

**UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS**

OLIVER SHIH, Individually and on behalf of all others similarly situated,

Plaintiff,

v.

AMYLYX PHARMACEUTICALS, INC., JOSHUA B. COHEN, JUSTIN B. KLEE, JAMES M.
FRATES, and MARGARET OLINGER,

Defendants.

Case No: 1:24-cv-12068-NMG

STIPULATION OF SETTLEMENT

This Stipulation of Settlement (together with all Exhibits thereto, the “Stipulation”), dated as of May 4, 2026, which is entered into by and among (i) the Lead Plaintiff Oliver Shih (“Plaintiff”), on behalf of himself and on behalf of the Settlement Class (as defined herein), and (ii) Defendants Amylyx Pharmaceuticals, Inc. (“Amylyx”), Joshua B. Cohen, Justin B. Klee, James M. Frates, and Margaret Olinger (collectively, “Defendants”, and together with Plaintiff, the “Parties”), by and through their undersigned attorneys, states all of the terms of the settlement and resolution of this matter by the Parties. This Stipulation is intended by the Parties to fully, finally, and forever compromise, settle, release, resolve, discharge, and dismiss with prejudice the Action (as defined herein) and all Released Claims (as defined herein) as against all Released Parties (as defined herein), subject to the final approval of the United States District Court for the District of Massachusetts (the “Court”). Throughout this Stipulation, all terms used with initial capitalization, but not immediately defined, shall have the meanings ascribed to them below.

WHEREAS:

I. The Action

A. On February 9, 2024, Plaintiff Shih filed a putative class action lawsuit in the United States District Court for the Southern District of New York alleging violations of the Securities Exchange Act of 1934 against Defendants (the “**Action**”) (Dkt. No. 1).

B. On April 23, 2024, the United States District Court for the Southern District of New York entered an order appointing Oliver Shih as Lead Plaintiff and Pomerantz LLP as Lead Counsel (Dkt. No. 30). On July 12, 2024, the Court issued an Order transferring the case to the District of Massachusetts (Dkt. No. 38). The case transferred under Docket No. 24-CV-12068 on August 12, 2024, and was assigned to Senior United States District Judge Nathaniel M. Gorton (Dkt. No. 40).

C. On June 24, 2024, Lead Plaintiff filed the Amended Class Action Complaint (the “**Amended Complaint**”) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 (Dkt. No. 33).

D. In September 2024, Defendants filed a Motion to Dismiss the Amended Complaint pursuant to Fed. R. Civ. P. 9(b) and 12(b)(6) and the Private Securities Litigation Reform Act, 15 U.S.C. §§78u-4 and 78u-5 (Dkt. No. 48). On September 30, 2025, the Court issued its Memorandum & Order denying Defendants’ Motion to Dismiss (Dkt. No. 55).

II. Settlement Negotiations

E. Following the Court’s denial of the Motion to Dismiss, the Parties engaged in arm’s-length settlement discussions. The Parties attended a mediation session with Michelle Yoshida of Phillips ADR on March 12, 2026. Prior to the mediation session, the Parties

exchanged detailed mediation statements. The Parties ultimately reached a settlement in principle to resolve the Action and have agreed to the terms set forth herein.

III. Defendants' Denial of Wrongdoing and Liability

F. Throughout the course of this Action, Defendants have denied, and continue to deny, any and all fault, liability, or wrongdoing of any kind. Defendants also have denied and continue to deny each and all of the claims and contentions alleged by Plaintiff on behalf of the Settlement Class. Without limiting the generality of the foregoing in any way, Defendants have denied and continue to deny, inter alia, that any misstatements or materially misleading omissions were made, that Defendants had any intent to defraud investors, that Plaintiff and the Settlement Class have suffered any damages, that the wrongdoing alleged in the Amended Complaint caused Plaintiff and the Settlement Class any damages, and that Plaintiff and the Settlement Class were harmed by the conduct alleged in the Action. Defendants are entering into this Stipulation solely to eliminate the uncertainty, distraction, burden, and expense of further litigation and the length of continued proceedings necessary to defend the Action through trial and appeals.

G. This Stipulation, whether or not consummated, any proceedings relating to any settlement of the Action, or any of the terms of the settlement of the Action, whether or not consummated, shall in no event be construed as, or deemed to be evidence of, an admission or concession by Defendants or any of the Released Parties with respect to any claim of any wrongdoing, fault, liability, or damages whatsoever, or any infirmity in any defense that Defendants have or could have asserted in the Action.

IV. Claims of Plaintiff and Benefits of Settlement

H. Plaintiff believes that the claims asserted in the Action have merit. Plaintiff, however, recognizes and acknowledges the expense and length of continued proceedings necessary to prosecute the Action against Defendants through trial and appeals. Plaintiff has also taken into account the uncertain outcome and the risk of any litigation. In particular, Plaintiff has considered the inherent problems of proof and possible defenses to the federal securities law violations asserted in the Action, including the defenses asserted by Defendants during the litigation, in motions on the pleadings, or during settlement negotiations. Plaintiff has therefore determined that the Settlement set forth in this Stipulation is fair, adequate, reasonable, and in the best interests of the Settlement Class.

NOW, THEREFORE, IT IS HEREBY STIPULATED AND AGREED, by and among Plaintiff, on behalf of himself and on behalf of the Settlement Class, and Defendants, by and through their respective undersigned counsel that, subject to the final approval of the Court pursuant to Rule 23(e) of the Federal Rules of Civil Procedure, in consideration of the benefits flowing to the Parties from the Settlement, the Action and the Released Claims as against the Released Parties shall be fully, finally, and forever compromised, settled, released, resolved, discharged, and dismissed with prejudice upon and subject to the terms and conditions of this Stipulation, as follows.

1. Definitions

In addition to the terms defined above, the following capitalized terms, used in this Stipulation, shall have the meanings specified below:

1.1. "Action" means the putative class action captioned *Shih v. Amylyx Pharmaceuticals, Inc. et al.*, Case No. 1:24-cv-12068-NMG (D. Mass.).

1.2. "Administrative Costs" means all costs and expenses associated with providing notice of the Settlement to the Settlement Class and otherwise administering or carrying out the terms of the Settlement. Such costs may include, without limitation: escrow agent costs, the costs of maintaining and administering the Escrow Account, the costs of publishing the Summary Notice, the costs of printing and mailing the Post-Card Notice and of emailing notice, as directed by the Court, and the costs of allocating and distributing the Net Settlement Fund to the Authorized Claimants. Such costs do not include legal fees and expenses.

1.3. "Alternative Judgment" means a form of final judgment that may be entered by the Court with the agreement of the Parties that is different from the Judgment attached hereto as Exhibit B.

1.4. "Amended Complaint" means the Amended Class Action Complaint for Violations of the Federal Securities Law filed by Lead Plaintiff in the Action on June 24, 2024.

1.5. "Authorized Claimant" means any Settlement Class Member who is a Claimant and whose claim for recovery has been allowed pursuant to the terms of this Stipulation, the exhibits hereto, and any order of the Court.

1.6. "Award to Plaintiff" means the requested reimbursement to Plaintiff for his reasonable costs and expenses (including lost wages) directly related to Plaintiff's representation of the Settlement Class in the Action.

1.7. "Business Day" means any day except Saturday or Sunday or any legal holiday, as defined in Rule 6(a)(6)(A) of the Federal Rules of Civil Procedure.

1.8. "Claimant" means any Settlement Class Member who files a Proof of Claim in such form and manner, and within such time, as the Court shall prescribe.

1.9. "Class Counsel" means Pomerantz LLP.

1.10. "Claims Administrator" means Strategic Claims Services ("SCS") or such other entity as the Court shall appoint to administer the Settlement.

1.11. "Defendants" means Amylyx Pharmaceuticals, Inc., Joshua B. Cohen, Justin B. Klee, James M. Frates, and Margaret Olinger.

1.12. "Defendants' Counsel" means Goodwin Procter LLP.

1.13. "Distribution Order" means an order entered by the Court authorizing and directing that the Net Settlement Fund be distributed, in whole or in part, to Authorized Claimants.

1.14. "Effective Date" with respect to the Settlement means the first date by which all of the events and conditions specified in ¶ 10.3 of this Stipulation have been met and have occurred or have been waived.

1.15. "Escrow Account" means an interest-bearing escrow account established by the Escrow Agent. The Escrow Account shall be managed by the Escrow Agent, subject to the Court's supervisory authority, for the benefit of Plaintiff and the Settlement Class in accordance with the terms of the Stipulation and any order of the Court.

1.16. "Escrow Agent" means Huntington National Bank. The Escrow Agent shall perform the duties as set forth in this Stipulation and any order of the Court.

1.17. "Final" means, with respect to any order of court, including but not limited to the Judgment, the Alternative Judgment, or any other court order, the latest to occur of the following: (i) the date as of which the time to seek review, alteration, or appeal of the Court's order has expired without any review, alteration, or appeal having been sought or taken; or (ii) if an appeal, petition, motion, or other application for review, alteration or amendment is filed, sought, or taken, the date as of which such appeal, petition, motion or other application shall have been finally determined in such a manner as to affirm the Court's original order in all material respects and the

time, if any, for seeking further review, including any petition for a writ of certiorari, has expired. Any proceeding or order, or any appeal or petition for a writ of certiorari or other form of review pertaining to the amount, payment, or allocation of attorneys' fees, the Plan of Allocation, or the provisions of ¶ 6.2 shall have no effect on finality for purposes of determining the date on which the Final Judgment or any Alternative Judgment becomes Final.

1.17a. "Final Approval Hearing" means the hearing at or after which the Court will make a final decision pursuant to Rule 23 of the Federal Rules of Civil Procedure as to whether the Settlement contained in the Stipulation is fair, reasonable, and adequate, and therefore, should receive final approval from the Court.

1.18. "Judgment" means the final order and judgment to be entered by the Court finally approving the Settlement and dismissing the Action with prejudice, materially in the form attached hereto as Exhibit B.

1.19. "Lead Counsel" means Pomerantz LLP.

1.20. "Lead Plaintiff" means Oliver Shih.

1.21. "Net Settlement Fund" means the Settlement Fund less: (a) Taxes; (b) Administrative Costs; (c) an Award to Plaintiff as may be approved by the Court; and (d) such attorneys' fees, costs, and expenses as may be approved by the Court.

1.22. "Notice" means the "Notice of Pendency and Proposed Settlement of Class Action," which is to be provided to Settlement Class Members substantially in the form attached hereto as Exhibit A-1.

1.23. "Opt-Out" means any one of, and "Opt-Outs" means all of, any Persons who otherwise would be Settlement Class Members and have timely and validly requested exclusion

from the Settlement Class in accordance with the provisions of the Preliminary Approval Order and the notice given pursuant thereto.

1.24. "Party" means any one of, and "Parties" means all of, the parties to the Stipulation, namely Defendants (as defined herein) and Plaintiff (on behalf of himself and the Settlement Class).

1.25. "Person" means individual, corporation, fund, limited liability corporation, professional corporation, limited liability partnership, partnership, limited partnership, association, joint stock company, estate, legal representative, trust, unincorporated association, government or any political subdivision or agency thereof, and any business or legal entity and their spouses, heirs, predecessors, successors, representatives, or assigns.

1.26. "Plaintiff" means Oliver Shih.

1.27. "Plan of Allocation" means a plan or formula for allocating the Net Settlement Fund to Authorized Claimants pursuant to this Stipulation, and which, subject to approval of the Court, shall be substantially in the form described in the Notice.

1.28. "Post-Card Notice" means the form of notice to be mailed to Settlement Class Members, substantially in the form attached hereto as Exhibit A-4.

1.29. "Preliminary Approval Order" means the proposed order preliminarily approving the Settlement (substantially in the form attached hereto as Exhibit A), approving dissemination of the notice thereof to the Settlement Class, and scheduling the Final Approval Hearing.

1.30. "Proof of Claim" means the Proof of Claim and Release Form to be submitted by Claimants, substantially in the form attached hereto as Exhibit A-2.

1.31. "Released Claims" means, to the fullest extent permitted by law or equity, claims, demands, losses, costs, interest, penalties, fees, attorneys' fees, expenses, rights, rights of recovery, causes of action, duties, obligations, judgments, actions, debts, sums of money, suits, contracts, agreements, promises, damages, and liabilities of every nature and description, including Unknown Claims, whether known or unknown, direct or indirect, representative, class, individual, asserted or unasserted, matured or unmatured, accrued or unaccrued, foreseen or unforeseen, disclosed or undisclosed, contingent or fixed or vested, at law or equity, whether arising under federal, state, local, foreign, statutory, common, administrative, or any other law, statute, rule, or regulation that the Releasing Parties: (a) asserted in the Action; (b) could have asserted or could in the future assert in this Action or any other action or in any forum, that arise from or out of, relate to, or are in connection with the claims, allegations, transactions, alleged or actual prohibited transactions or breaches of duty (including fiduciary duty), facts, events, acts, disclosures, matters or occurrences, errors, statements, representations, actions, failures to act or omissions involved, alleged, described, set forth, or referred to in the complaint and amended complaint filed in the Action, or that arise from or out of, relate to, directly or indirectly, or are in connection with the holding, purchase, acquisition, or sale of Amylyx securities during the Settlement Class Period (including, without limitation, claims for fraud and negligent misrepresentation); or (c) that arise out of, relate to, or are based on the settlement or resolution of the Action; provided, however, that Released Claims do not include claims to enforce this Stipulation. Released Claims do not include claims asserted in the derivative actions currently pending in the District of Massachusetts and Delaware Chancery Court.

1.32. "Released Parties" means (a) any and all of the Defendants and any person, partnership, firm, corporation, limited liability company, trust, or other entity or organization in

which any Defendant has a controlling interest or which is or was related to or affiliated with any of the Defendants; (b) with respect to each of the Persons in subsection (a), their respective past, present and future directors, officers, employees, managers, controlling shareholders, servants, insurers, co-insurers, reinsurers, attorneys, agents, partners, limited partners, principals, members, trustees, advisors, investment advisors, auditors, accountants, trustees, underwriters, investment bankers, consultants, subsidiaries, parents, any other entity in which any such parent has a controlling interest or which is or was related to or affiliated with any such parent, successors, predecessors, heirs, immediate family members, and anyone acting or purporting to act for or on behalf of any of them or their successors; and (c) the legal representatives, predecessors, heirs, successors and assigns of any of the foregoing.

1.33. "Released Parties' Claims" means all claims, demands, rights, remedies, liabilities, and causes of action of every nature and description whatsoever, whether based on federal, state, local, statutory, or common law, or any other law, rule, or regulation, including both known and Unknown Claims, that arise out of or relate in any way to the institution, prosecution, or Settlement of this Action, including but not limited to all claims for malicious prosecution or sanctions. "Released Parties' Claims" do not include claims to enforce any of the terms of this Stipulation or the Judgment or Alternative Judgment, if applicable.

1.34. "Releasing Parties" means Plaintiff, each and every Settlement Class Member and each of their respective parent entities, associates, affiliates, subsidiaries, predecessors, successors, assigns, attorneys, immediate family members, heirs, representatives, administrators, executors, devisees, legatees, and estates.

1.35. "Settlement" means the settlement contemplated by this Stipulation.

1.36. "Settlement Amount" means the sum of \$6,500,000 (Six Million Five Hundred Thousand U.S. Dollars). The Settlement Amount includes all Administrative Costs, Lead Counsel's attorneys' fees and expenses (as allowed by the Court), Award to Plaintiff (as allowed by the Court), Settlement Class Member benefits, as well as any other costs, expenses, or fees of any kind whatsoever associated with the Settlement.

1.37. "Settlement Class" means all those who purchased or otherwise acquired Amylyx securities between November 11, 2022 and November 8, 2023, inclusive, and who were damaged thereby. Excluded from the Settlement Class are Defendants; the officers and directors of Amylyx during the Settlement Class Period; members of their immediate families and their legal representatives, heirs, agents, affiliates, successors or assigns; Defendants' liability insurance carriers, and any affiliates or subsidiaries thereof; any entity in which Defendants or their immediate families have or had a controlling interest during the Settlement Class Period; and those persons who exclude themselves by submitting a request for exclusion from the Settlement Class that is accepted by the Court.

1.38. "Settlement Class Member" means any one of, and "Settlement Class Members" means all of, the members of the Settlement Class.

1.39. "Settlement Class Period" means the period from November 11, 2022 through November 8, 2023, inclusive.

1.40. "Settlement Fund" means the Settlement Amount and any interest or other income earned thereon.

1.42. "Summary Notice" means the notice, substantially in the form attached hereto as Exhibit A-3, to be published as set forth in the Preliminary Approval Order.

1.42a. "Supplemental Agreement" means the separate confidential agreement executed concurrently with the execution of the Stipulation of Settlement providing that Defendants shall have the option to terminate the Settlement upon the conditions specified therein.

1.43. "Taxes" means: (a) all federal, state and/or local taxes of any kind (including any interest or penalties thereon) on any income earned by the Settlement Fund; (b) the expenses and costs incurred by Lead Counsel in connection with determining the amount of, and paying, any taxes owed by the Settlement Fund (including, without limitation, expenses of tax attorneys and accountants and mailing and distribution costs and expenses or penalties relating to the filing or failure to file all necessary or advisable tax returns); and (c) all taxes imposed on payments by the Settlement Fund, including withholding taxes.

1.44. "Unknown Claims" means (i) any Released Claims which Plaintiff, any Settlement Class Member, or any Releasing Party does not know or suspect to exist in his, her, or its favor at the time of the Effective Date, and (ii) any Released Parties' Claims which any Defendant or Released Party does not know or suspect to exist in his, her, or its favor at the time of the Effective Date, which, if known by him, her, or it, might have affected his, her, or its decisions with respect to this Settlement, or any Settlement Class Member's or Releasing Party's decision not to opt-out or object to this Settlement. With respect to any and all Released Claims or Releasing Parties' Claims, the Parties stipulate and agree that, upon the Effective Date, Plaintiff and Defendants shall expressly waive, and each of the Settlement Class Members, Releasing Parties, and Released Parties shall be deemed to have waived, and by operation of the Judgment or Alternative Judgment, if applicable, shall have waived, the provisions, rights and benefits of California Civil Code § 1542, which provides:

A general release does not extend to claims which the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the

release, and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

Plaintiff and Defendants acknowledge, and each of the Settlement Class Members, the Releasing Parties, and/or the Released Parties shall be deemed by operation of law to have acknowledged, that they may hereafter discover facts in addition to or different from those which he, she, or it now knows or believes to be true with respect to the subject matter of the Released Claims or Releasing Parties' Claims, but the Defendants and Plaintiff shall expressly, fully, finally, and forever settle and release, and each Settlement Class Member, Releasing Party, or Released Party, upon the Effective Date, shall be deemed to have, and by operation of the Judgment or Alternative Judgment, if applicable, shall have, fully, finally, and forever settled and released, any and all Released Claims or Released Parties' Claims, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of fiduciary duty, law, or rule, without regard to the subsequent discovery or existence of such different or additional facts. Plaintiff and Defendants acknowledge, and each of the other Settlement Class Members, Releasing Parties, and Released Parties shall be deemed by operation of law to have acknowledged, that the foregoing waiver was separately bargained for and a key element of the Settlement.

2. The Settlement Consideration

2.1. In consideration of the full and final release, settlement and discharge of all Released Claims against the Released Parties, Amylyx shall, within the later of fifteen (15) Business Days after (a) the date of entry of the Preliminary Approval Order or (b) receipt by Amylyx and its insurers of all information necessary to permit them to make payment by wire

(including payee, tax identification number, wire transfer instructions, and an executed Form W-9 for the recipient of the deposit, and contact information, including a name and phone number, for the person(s) or entity maintaining the Escrow Account), pay, or cause to be paid, the Settlement Amount by wire transfer, to the Escrow Account, provided that Amylyx must, no later than two (2) business days after the filing of the motion for preliminary approval of the Settlement, provide Lead Counsel with the contact information (including email addresses) for the persons to whom the above-noted information is to be provided.

2.2. Payment of the Settlement Amount shall be Defendants' sole monetary obligation under the Settlement. Under no circumstances will Defendants or the Released Parties be required to pay, or cause payment of, more than the Settlement Amount pursuant to this Stipulation and the Settlement for any reason whatsoever, including, without limitation, as compensation to any Settlement Class Member or in payment of any fees or expenses incurred by any Settlement Class Member or Lead Counsel.

3. Handling and Disbursement of Funds by the Escrow Agent

3.1. No monies will be disbursed from the Settlement Fund until after the Effective Date except: (a) as provided in ¶ 3.4 and ¶ 8.2 below; (b) as provided in ¶ 10.6 below, if applicable; and (c) to pay Taxes on the income earned by the Settlement Fund. Taxes shall be paid out of the Settlement Fund and shall be considered to be a cost of administration of the Settlement and shall be timely paid by the Escrow Agent without prior Order of the Court.

3.2. The Escrow Agent shall invest the Settlement Fund and all interest accrued thereon exclusively in United States Treasury Bills (or a mutual fund invested solely in such instruments), except that any residual cash balances up to the amount that is insured by the FDIC may be deposited in any account that is fully insured by the FDIC. The escrow agreement shall provide

that, until the Escrow Agent receives joint notification from Lead Counsel and Defendants' Counsel that the Effective Date has occurred, any withdrawal from the Escrow Account, other than for the payment of Taxes and Administrative Costs prior to final approval of the settlement, shall require a signature from Defendants' Counsel. Defendants, Defendants' Counsel, and the other Released Parties shall have no responsibility for, interest in, or any liability whatsoever with respect to any investment or management decisions executed by the Escrow Agent. The Settlement Fund shall bear all risks related to the investments of the Settlement Amount in accordance with the guidelines set forth in this ¶ 3.2.

3.3. The Escrow Agent shall not disburse the Settlement Fund except as provided in this Stipulation or by an order of the Court. Defendants shall have prompt access to records of the Escrow Account upon request.

3.4. Prior to the Effective Date, the Escrow Agent may, without further approval from the Court, disburse at the direction of Class Counsel up to \$300,000 from the Settlement Fund for Administrative Costs. In the event that the Settlement is not consummated, money paid or incurred for Administrative Costs, including any related fees, shall not be returned or repaid to Amylyx or its insurers. Any dispute concerning whether a failure to provide approval called for by the Settlement Agreement or this Stipulation was reasonable shall be submitted to the Court.

4. Taxes

4.1. The Parties agree to treat the Settlement Fund as being at all times a "qualified settlement fund" within the meaning of Treasury Regulation § 1.468B-1. In addition, Lead Counsel or their designee shall timely make such elections as necessary or advisable to carry out the provisions of this § 4, including the "relation-back election" (as defined in Treasury Regulation § 1.468B-1) back to the earliest permitted date. Such elections shall be made in compliance with

the procedures and requirements contained in such regulations. It shall be the responsibility of Lead Counsel or their designee to timely and properly prepare and deliver the necessary documentation for signature by all necessary parties, and thereafter to cause the appropriate filing to occur.

4.2. For purposes of § 468B of the Internal Revenue Code of 1986, as amended, and Treasury Regulation § 1.468B-2(k)(3) promulgated thereunder, the “administrator” shall be Lead Counsel or their designee. Lead Counsel or their designee shall timely and properly file all informational and other tax returns necessary or advisable with respect to the Settlement Fund. Such returns shall be consistent with this § 4 and in all events shall reflect that all Taxes on the income earned by the Settlement Fund shall be paid out of the Settlement Fund.

4.3. All Taxes arising with respect to the income earned by the Settlement Fund, including any Taxes or tax detriments that may be imposed upon Defendants or their counsel with respect to any income earned by the Settlement Fund for any period during which the Settlement Fund does not qualify as a “qualified settlement fund” for federal or state income tax purposes, and expenses and costs incurred in connection with the operation and implementation of this § 4, shall be paid out of the Settlement Fund, as appropriate. Defendants, their counsel and the other Released Parties shall have no liability or responsibility for the Taxes. Taxes shall be treated as, and considered to be, a cost of administration of the Settlement and shall be timely paid out of the Settlement Fund without prior order from the Court.

5. Preliminary Approval Order, Notice Order, and Final Approval Hearing

5.1. Within two (2) business days of the execution of this Stipulation, Lead Plaintiff will move for preliminary approval of the Settlement, certification of the Settlement Class for settlement purposes only, and the scheduling of a hearing for consideration of final approval of the

Settlement (“Preliminary Approval Motion”). Lead Counsel shall submit this Stipulation and its exhibits to the Court and shall apply for entry of a preliminary approval order in the form of Exhibit A hereto, seeking, among other things, approval (1) for the mailing of the Post-Card Notice in the form of Exhibit A-4 hereto, (2) for the posting of the Notice in the form of Exhibit A-1 hereto on the internet, (3) for the publication of Summary Notice in the form of Exhibit A-3 hereto, and (4) of the Proof of Claim form in the form attached as Exhibit A-2 hereto.

5.2. To assist in dissemination of notice, Amylyx will cooperate in obtaining from the Company’s transfer records, information concerning the identity of Settlement Class Members, including any names, addresses, and email addresses (to the extent email addresses are available) of Settlement Class Members and nominees or custodians that exist in such transfer records (“Settlement Class Information”). The Company shall provide, or cause to be provided, to Lead Counsel or the Claims Administrator, at no cost to Plaintiff, within one hundred (100) calendar days prior to the date set by the Court for the final approval of the Settlement, transfer records in electronic searchable form, such as Excel, containing the Settlement Class Information. Defendants shall pay the costs, if any, of providing their transfer records to Lead Plaintiff’s Counsel and providing CAFA notice.

5.3. At the time of the submission described in ¶ 5.1 hereof, the Parties, through their counsel, shall jointly request that, after the Notice is provided, the Court hold the Final Approval Hearing and (i) approve the Settlement as set forth herein and (ii) enter a Judgment substantially in the form of Exhibit B hereto, as promptly after the Final Approval Hearing as possible.

5.4. The Settlement is expressly conditioned upon, among other things, the entry of a Judgment substantially in the form attached hereto as Exhibit B or an Alternative Judgment.

Plaintiff, by and through Lead Counsel, shall move for entry of the Judgment, including, among other things, the releases described herein.

6. Releases and Covenants Not to Sue

6.1. Upon the Effective Date, the Releasing Parties, on behalf of themselves, their past, present, and future heirs, executors, administrators, trustees, predecessors, successors and assigns, and any other Person claiming (now or in the future) to be acting on behalf of any of them, regardless of whether any such Releasing Party ever seeks or obtains by any means, including without limitation by submitting a Proof of Claim, any disbursement from the Settlement Fund, (a) shall have and be deemed to have, and by operation of the Judgment, or Alternative Judgment, shall have, irrevocably and unconditionally, fully, finally, and forever released, waived, relinquished, discharged, and dismissed, with prejudice, all Released Claims against the Released Parties; (b) shall have and be deemed to have covenanted not to sue, directly or indirectly any Released Party with respect to any and all of the Released Claims; and (c) shall be forever and permanently barred and enjoined from directly or indirectly filing, commencing, instituting, continuing, asserting, intervening in, or prosecuting, or assisting any Person in instituting, continuing, asserting or prosecuting in any forum, any Released Claim, in any capacity, against any of the Released Parties.

6.2. Upon the Effective Date, Defendants, on behalf of themselves, their heirs, executors, predecessors, successors, and assigns, shall be deemed to have, and by operation of the Judgment, or Alternative Judgment, shall have fully, finally, and forever released, waived, relinquished, and discharged Plaintiff, Settlement Class Members, and Lead Counsel from all Released Parties' Claims, and shall be permanently enjoined from prosecuting the Released Parties' Claims against Plaintiff, Settlement Class Members, and Lead Counsel.

6.3. Nothing contained herein shall bar the Releasing Parties, Defendants, or any Released Party from bringing any action or claim to enforce the terms of this Stipulation or the Judgment or Alternative Judgment, if applicable.

6.4. The releases and waivers contained in this Section were separately bargained for and are essential elements of this Stipulation and the Settlement.

7. Administration and Calculation of Claims, Final Awards and Supervision and Distribution of the Settlement Fund

7.1. Under the supervision of Lead Counsel, acting on behalf of the Settlement Class, and subject to such supervision and direction of the Court as may be necessary or as circumstances may require, the Claims Administrator shall administer and calculate the claims submitted by Settlement Class Members and shall oversee distribution of the Net Settlement Fund to Authorized Claimants. The Released Parties shall not have any role in, or responsibility or liability to any Person for, the administration of the Settlement or the solicitation, review, or evaluation of Proofs of Claim, nor shall any discovery be taken of Defendants in connection therewith.

7.2. The Settlement Fund shall be applied as follows: (a) to pay the Taxes described in § 4 above; (b) to pay Administrative Costs; (c) to pay Lead Counsel's attorneys' fees and expenses and Award to Plaintiff for reimbursement of their time and expenses pursuant to ¶ 8.1 below, to the extent allowed by the Court; and (d) to distribute the balance of the Net Settlement Fund to the Authorized Claimants as allowed by this Stipulation, the Plan of Allocation, or the Court.

7.3. Upon and after the Effective Date, the Net Settlement Fund shall be distributed to Authorized Claimants in accordance with the terms of the Plan of Allocation set forth in the Notice and any orders of the Court.

7.4. This is not a claims-made settlement, and if all conditions of the Stipulation are satisfied and the Judgment or Alternative Judgment becomes Final, no portion of the Settlement

Fund will be returned to Amylyx. Defendants, their counsel and the other Released Parties shall have no responsibility for, involvement in, interest in, or liability whatsoever with respect to the investment or distribution of the Net Settlement Fund, the Plan of Allocation, the determination, administration, or calculation of claims, the payment or withholding of Taxes or tax expenses, or any losses incurred in connection therewith.

7.5. It is understood and agreed by the Parties that any proposed Plan of Allocation of the Net Settlement Fund, including any adjustments to an Authorized Claimant's claim set forth therein, is not a condition of this Stipulation and is to be considered by the Court separately from the Court's consideration of the fairness, reasonableness, and adequacy of the Settlement set forth in this Stipulation.

7.6. Lead Counsel will apply to the Court, on notice to Defendants' Counsel, for a Distribution Order: (a) approving the Claims Administrator's administrative determinations concerning the acceptance and rejection of the Proofs of Claim submitted; (b) approving payment of any fees and expenses associated with the administration of the Settlement from the Escrow Account; and (c) if the Effective Date has occurred, directing payment of the Net Settlement Fund to Authorized Claimants from the Escrow Account.

8. Lead Counsel's Attorneys' Fees and Reimbursement of Expenses

8.1. Lead Counsel may submit an application or applications (the "Fee and Expense Application") for distributions from the Settlement Fund to Lead Counsel for (a) an award of attorneys' fees not to exceed one-third of the Settlement Amount, (b) reimbursement of reasonable costs and expenses actually incurred, including the fees and expenses of experts and/or consultants incurred in connection with prosecuting the Action, and (c) an Award to Plaintiff of not more than \$2,500 in total for reimbursement of his time and expenses in connection with the Action

(collectively, the “Fee and Expense Award”). Defendants shall take no position with respect to the Fee and Expense Application(s) or the Fee and Expense Award.

8.2. Except as otherwise provided in this paragraph, the Fee and Expense Award shall be paid to Lead Counsel from the Settlement Fund within two (2) Business Days after the date the Court enters the Judgment or Alternative Judgment, if applicable, and an order awarding such fees and expenses, notwithstanding any objections to or appeals of such order or of the Judgment or Alternative Judgment, if applicable. In the event that the Effective Date does not occur, or the Fee and Expense Award is reduced or reversed in whole or in part on appeal or further review, then Lead Counsel shall be obligated to refund to the Escrow Account, within ten (10) Business Days from receiving notice of such event, an amount consistent with such reduction or reversal, including accrued interest.

8.3. The procedure for, and allowance or disallowance by the Court of, the Fee and Expense Application are not conditions of the Settlement set forth in this Stipulation and are to be considered by the Court separately from the Court’s consideration of the fairness, reasonableness, and adequacy of the Settlement. None of the Parties may terminate or cancel the Settlement on the basis of the amount of any Fee and Expense Award.

8.4. Any award of attorneys’ fees and/or expenses to Lead Counsel or Award to Plaintiff shall be paid solely from the Settlement Fund and shall reduce the settlement consideration paid to the Settlement Class accordingly. No Defendant shall have any responsibility for payment of Lead Counsel’s attorneys’ fees and expenses or other awards to Plaintiff beyond the obligation of Amylyx to fund the Settlement Amount as set forth in ¶ 2.1 above.

9. Class Certification

9.1. The Parties hereby stipulate, for purposes of the Settlement only, to: (a) certification of the Action as a class action pursuant to Rule 23(b)(3) of the Federal Rules of Civil Procedure; (b) appointment of Plaintiff as the class representative; and (c) appointment of Lead Counsel as class counsel for the Settlement Class pursuant to Rule 23(g). In the event that the Judgment or Alternative Judgment, if applicable, does not become Final or the Settlement fails to become effective for any reason, the Parties reserve all their rights on all issues. In such an event, Defendants reserve all rights to object to and oppose class certification or challenge the standing of Plaintiff or any other intervening plaintiff, and this Stipulation shall not be offered as evidence of any agreement, admission, or concession that any class should be or remain certified in the Action or that any plaintiff has standing.

10. Conditions of Settlement, Effect of Disapproval, Cancellation or Termination

10.1. Plaintiff, on behalf of the Settlement Class, and Defendants shall, each in their separate discretions, have the right to terminate the Settlement and Stipulation (a “Termination”) by providing written notice of their or its election to do so to all other Parties within thirty (30) calendar days of: (i) the Court declining to enter the Preliminary Approval Order in any material respect; (ii) the Court refusing to approve this Stipulation in any material respect; (iii) the Court declining to enter the Judgment, or an Alternative Judgment acceptable to the Parties, in any material respect; or (iv) the date upon which the Final Judgment is modified or reversed by the Court, the United States Court of Appeals, or the United States Supreme Court in any material respect.

10.2. If the Settlement Amount is not paid into the Escrow Account in accordance with ¶ 2.1 of this Stipulation, then Plaintiff, on behalf of the Settlement Class, shall have the right to, at any time prior to the Court’s entry of the Final Judgment, (a) terminate the Settlement and

Stipulation by providing written notice to Defendants or (b) enforce the terms of the Settlement and this Stipulation and seek a judgment effecting the terms herein, subject to Defendants' right to cure any failure to pay within five (5) Business Days of receiving written notice of such deficiency.

10.3. The Effective Date of this Stipulation and the Settlement incorporated therein shall be the date on which all of the following events have occurred or been waived: (a) the Court has entered the Preliminary Approval Order set forth in Exhibit A attached hereto; (b) the Settlement Amount has been deposited into the Escrow Account, as set forth in ¶ 2.1; (c) Defendants have not exercised their option to terminate the Settlement pursuant to the provisions of this Stipulation; (d) Plaintiff has not exercised his option to terminate the Settlement pursuant to the provisions of this Stipulation; (e) the Court has approved the Settlement as described herein, following notice to the Settlement Class and a hearing, as prescribed by Rule 23 of the Federal Rules of Civil Procedure; and (f) the Court has entered the Judgment, and the Judgment has become Final, or the Court has with the consent of the Parties entered an Alternative Judgment and none of the Parties has sought to terminate the Alternative Judgment and it has become Final.

10.4. Upon the occurrence of the Effective Date, any and all interest or right of Defendants in or to the Settlement Fund, if any, shall be absolutely and forever extinguished, except as set forth in this Stipulation, and the releases herein shall be effective.

10.5. If prior to Judgment or Alternative Judgment, if applicable, Persons who otherwise would be Settlement Class Members have filed with the Court valid and timely requests for exclusion from the Settlement Class in accordance with the provisions of the Preliminary Approval Order and the notice given pursuant thereto ("Opt-Outs"), and such Persons in the aggregate purchased securities during the Settlement Class Period in an amount greater than the amount

specified in a separate Supplemental Agreement between the Parties (the “Supplemental Agreement”), then Defendants acting unanimously shall have the option to terminate this Stipulation and Settlement in strict accordance with the requirements and procedures set forth in the Supplemental Agreement.

10.6. If the Settlement is terminated by Plaintiff or Defendants; the Court does not approve the Settlement; the Judgment, or Alternative Judgment, if any, does not or cannot become Final; or the Effective Date otherwise fails to occur, then: (a) this Stipulation shall be without force and effect upon the rights of the Parties; (b) the Parties shall be restored to their respective positions in the Action immediately prior to the date of this Stipulation, and they shall proceed in all respects as if the Stipulation had not been executed and the related orders had not been entered, and all of their respective claims and defenses as to any issue in the Action shall be preserved without prejudice; (c) the terms and provisions of this Stipulation shall have no further application with respect to the Parties and shall not be used in the Action or in any other proceeding for any purpose; and (d) within seven (7) Business Days after the occurrence of such event, Plaintiff shall return to Amylyx any monies remaining in the Escrow Account, including any accrued interest thereon, but less any Administrative Costs that were reasonably and actually incurred and paid or payable from the Settlement Fund as of the date of termination and any Taxes actually incurred and paid or payable as of the date of termination.

10.7 Plaintiff shall have the right to terminate the Settlement in the event that any material terms of the Settlement are breached. In addition to the grounds set forth above, Defendants shall have the right to terminate the Settlement in the event that any material terms of the Settlement are breached or Settlement Class Members timely and validly requesting exclusion from the Settlement Class meet the conditions set forth in Defendants’ confidential Supplemental

Agreement with Plaintiff, in accordance with the terms of that agreement. The Supplemental Agreement, which is being executed concurrently herewith, shall not be filed with the Court and its terms shall not be disclosed in any other manner (other than the statements herein and in the Notice, to the extent necessary, or as otherwise provided in the Supplemental Agreement) unless and until the Court otherwise directs or a dispute arises between Plaintiff and Defendants concerning its interpretation or application, in which event the Parties shall submit the Supplemental Agreement to the Court *in camera* and request that the Court afford it confidential treatment.

11. No Admission of Liability or Wrongdoing

11.1. This Stipulation (whether or not it is consummated or terminated), including the exhibits hereto and the Plan of Allocation contained therein, all matters arising in connection with such negotiations, proceedings or agreements, and all acts performed or documents executed pursuant to or in furtherance of this Stipulation: (a) do not constitute, and shall not be offered or received against Defendants or any other Released Party as evidence of, or construed as, or deemed to be evidence of any presumption, concession, or admission of any kind; (b) do not constitute, and shall not be offered or received against any of the Defendants as evidence of an admission by any of those Defendants with respect to the truth of any fact alleged in the Amended Complaint or the validity of any Released Claim, or the deficiency of any defense that has been or could have been asserted in the Action or in any other litigation, or of any liability, damages, negligence, fault, or wrongdoing of the Defendants; (c) do not constitute, and shall not be offered or received against Defendants or any other Released Party as evidence of a presumption, concession, or admission of any fault, misstatement, or omission with respect to any statement or written document approved or made by Defendants; (d) do not constitute, and shall not be offered or received against

Defendants or any other Released Parties as evidence of a presumption, concession, or admission with respect to any liability, damages, negligence, fault, infirmity, or wrongdoing in any other civil, criminal, or administrative action or proceeding; (e) do not constitute, and shall not be construed against Defendants or any other Released Parties as an admission or concession that the consideration to be given hereunder represents the amount that could be or would have been recovered after trial; (f) shall not be construed as or received in evidence as an admission, concession, or presumption against Plaintiff or any of the Settlement Class Members that any of their claims are without merit, or that any defenses asserted by the Defendants have any merit, or that damages recoverable in the Action would not have exceeded the Settlement Amount; and (g) shall not, in the event the Settlement is terminated as described in this Stipulation, be used by any Party for any purpose in any trial in this Action.

11.2. The Parties may file or refer to this Settlement and the Judgment or Alternative Judgment, if applicable, to (a) effectuate the liability protection granted thereunder, including without limitation to support a defense or counterclaim based on principles of res judicata, collateral estoppel, release, good-faith settlement, judgment bar or reduction, or any theory of claim preclusion or issue preclusion or similar defense or counterclaim, or (b) effectuate the liability protections granted them under any applicable insurance policies.

12. Miscellaneous Provisions

12.1. The Parties acknowledge that it is their intent to consummate the Settlement and agree to cooperate to the extent reasonably necessary to effectuate and implement all terms and conditions of the Stipulation and use their best efforts to accomplish the terms and conditions of the Stipulation.

12.2. The Parties and their counsel represent that they will not encourage or otherwise influence (or seek to influence) any Settlement Class Members to request exclusion from, or object to, the Settlement, the Plan of Allocation, or Lead Counsel's Fee and Expense Application.

12.3. Each of the attorneys executing this Stipulation, any of its exhibits, or any related settlement documents on behalf of any Party hereto hereby warrants and represents that he or she has been duly empowered and authorized to do so by the Party he or she represents.

12.4. Plaintiff and Lead Counsel represent and warrant that none of the Plaintiff's Claims or causes of action against one or more Defendants in the Action, or referred to in this Stipulation, or that could have been alleged against one or more Defendants in the Action, have been assigned, encumbered, conveyed, given, granted, or in any manner transferred in whole or in part.

12.5. This Stipulation, together with its exhibits and the Supplemental Agreement, constitutes the entire agreement between the Parties related to the Settlement and supersedes any prior agreements. In the event that there exists a conflict or inconsistency between the terms of this Stipulation and the terms of any exhibit attached hereto, the terms of the Stipulation shall prevail.

12.6. The Parties agree that no Party was or is a "prevailing party" in the Action. Except as otherwise provided herein, each Party shall bear its own costs.

12.7. While retaining their right to deny that the claims asserted in the Action were meritorious, Defendants and Defendants' Counsel, in any statement made to any media representative (whether or not for attribution) will not assert that the Action was commenced or prosecuted in bad faith nor will they deny that the Action is being settled voluntarily after consultation with competent legal counsel. In all events, Plaintiff and his counsel and Defendants and Defendants' Counsel shall not make any accusations of wrongful or actionable conduct by any

Party concerning the prosecution, defense, and resolution of the Action, and shall not otherwise suggest that the Settlement constitutes an admission of any claim or defense alleged.

12.8. This Stipulation may not be modified or amended, nor may any of its provisions be waived, except by a writing signed by all Parties or their counsel or their respective successors in interest.

12.9. This Stipulation shall be binding upon, and shall inure to the benefit of, the Parties and their respective agents, successors, executors, heirs, and assigns, including any Released Parties, and any corporation, partnership, or other entity into or with which any Party may merge, consolidate, or reorganize.

12.10. The headings herein are used for the purpose of convenience only and are not meant to have legal effect.

12.11. Each counsel or other Person executing this Stipulation and any documents prepared in furtherance of it on behalf of any Party hereto hereby warrants that such Person has the full authority to do so.

12.12. This Stipulation may be executed in any number of counterparts by any of the signatories hereto and the transmission of an original signature page electronically (including by facsimile or portable document format) shall constitute valid execution of the Stipulation as if all signatories hereto had executed the same document.

12.13. The construction, interpretation, operation, effect, and validity of this Stipulation, the Supplemental Agreement, and the Settlement, and any and all disputes arising out of or relating in any way to this Stipulation and Settlement, whether in contract, tort or otherwise, shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without regard to conflict of laws principles.

12.14. The Court shall retain jurisdiction with respect to the implementation and enforcement of the terms of this Stipulation, and all parties hereto submit to the jurisdiction of the Court for purposes of implementing and enforcing the Settlement embodied in this Stipulation. Any action arising under or to enforce this Stipulation or any portion thereof shall be commenced and maintained only in the Court.

12.15. The Stipulation shall not be construed more strictly against one Party than another merely by virtue of the fact that it, or any part of it, may have been prepared by counsel for one of the Parties, it being recognized that it is the result of arm's length negotiations between the Parties, and all Parties have contributed substantially and materially to the preparation of this Stipulation.

12.16. All agreements by, between or among the Parties, their counsel and their other advisors as to the confidentiality of information exchanged between or among them shall remain in full force and effect and shall survive the execution and any termination of this Stipulation and the final consummation of the Settlement.

12.17. The Parties shall not assert or pursue any action, claim, or rights that any party violated any provision of Rule 11 of the Federal Rules of Civil Procedure and/or the Private Securities Litigation Reform Act of 1995 in connection with the Action, the Settlement, the Stipulation, or the Supplemental Agreement. The Parties agree that the Action was resolved in good faith following arm's-length bargaining, and that the Action was brought and defended in full compliance with applicable requirements of good faith litigation under the Securities Exchange Act of 1934 and Rule 11 of the Federal Rules of Civil Procedure.

12.18. Any failure by any of the Parties to insist upon the strict performance by any other Party of any of the provisions of the Stipulation shall not be deemed a waiver of any of the provisions hereof, and such Party, notwithstanding such failure, shall have the right thereafter to

insist upon the strict performance of any and all of the provisions of this Stipulation to be performed by the other Parties.

12.19. No opinion or advice concerning the tax consequences of the proposed Settlement to individual Settlement Class Members is being given or will be given by the Parties or their counsel; nor is any representation or warranty in this regard made by virtue of this Stipulation. Each Settlement Class Member's tax obligations, and the determination thereof, are the sole responsibility of the Settlement Class Member, and it is understood that the tax consequences may vary depending on the particular circumstances of each individual Settlement Class Member.


12.20. Upon execution of the Stipulation, the Parties may publicly disclose the Settlement Amount and source(s) of funds for such Settlement Amount. In addition, upon execution of this Stipulation, the Parties may disclose the terms of the Stipulation to the Parties' advisors as necessary, including accountants, auditors, and/or tax advisors.

IN WITNESS WHEREOF, the Parties have executed this Stipulation by their undersigned counsel effective as of the date set forth below.

Dated: May 4, 2026

Respectfully submitted,

POMERANTZ LLP



Jeremy A. Lieberman
Samantha Daniels
600 Third Avenue, 20th Floor
New York, New York 10016
Telephone: (212) 661-1100
Facsimile: (917) 463-1044
jalieberman@pomlaw.com
sdaniels@pomlaw.com

*Counsel for Oliver Shih and Lead Counsel for
the Class*

GOODWIN PROCTER LLP



Caroline H. Bullerjahn
100 Northern Avenue
Boston, MA 02210
Tel.: 617-570-1000
Fax: 617-523-1231
cbullerjahn@goodwinlaw.com

Counsel for Defendants

CERTIFICATE OF SERVICE

I hereby certify that on May 4, 2026, a true and correct copy of the foregoing **STIPULATION OF SETTLEMENT** was served by CM/ECF to the parties registered to the Court's CM/ECF system.

/s/ Samantha Daniels

EXHIBIT A

**UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS**

OLIVER SHIH, Individually and on behalf of
all others similarly situated,

Plaintiff,

v.

AMYLYX PHARMACEUTICALS, INC.,
JOSHUA B. COHEN, JUSTIN B. KLEE,
JAMES M. FRATES, and MARGARET
OLINGER,

Defendants.

Case No: 1:24-cv-12068-NMG

**[PROPOSED] PRELIMINARY
APPROVAL ORDER**

WHEREAS, Lead Plaintiff Oliver Shih (“Plaintiff”), individually and on behalf of the Settlement Class, and Defendants Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”), Joshua B. Cohen, Justin B. Klee, James M. Frates, and Margaret Olinger (collectively, the “Defendants”, and together with Plaintiff, the “Settling Parties”), have entered into a Stipulation of Settlement, dated May 4, 2026 (the “Settlement Stipulation”), which is subject to review under Rule 23 of the Federal Rules of Civil Procedure and which, together with the exhibits annexed thereto, sets forth the terms and conditions for the proposed settlement and dismissal of the putative class action pending before the Court entitled *Shih v. Amylyx Pharmaceuticals, Inc. et al.*, Case No. 1:24-cv-12068-NMG (D. Mass.) (the “Action”); and the Court having read and considered the Settlement Stipulation and the exhibits thereto and submissions made relating thereto, and finding that substantial and sufficient grounds exist for entering this Order; and the Settling Parties having consented to the entry of this Order;

NOW, THEREFORE, IT IS HEREBY ORDERED, this ____ day of _____, 20____, that:

1. Definitions. Unless otherwise defined herein, capitalized terms used herein have the meanings defined in the Settlement Stipulation.

2. Jurisdiction. This Court has jurisdiction over the subject matter of this Action and over the Settling Parties.

3. Preliminary Findings as to Settlement Class. This Court finds, preliminarily and for purposes of this Settlement only, that the prerequisites for a class action under Rules 23(a) and (b)(3) of the Federal Rules of Civil Procedure have been satisfied in that: (a) the number of Settlement Class Members is so numerous that joinder of all members of the Settlement Class is impracticable; (b) there are questions of law and fact common to the Settlement Class; (c) Plaintiff's claims are typical of the claims of the Settlement Class he seeks to represent; (d) Plaintiff fairly and adequately represents the interests of the Settlement Class; (e) questions of law and fact common to the Settlement Class predominate over any questions affecting only individual members of the Settlement Class; and (f) a class action is superior to other available methods for the fair and efficient adjudication of the Action.

4. Certification of the Settlement Class. Pursuant to Rule 23(a) and (b)(3) of the Federal Rules of Civil Procedure and for the purposes of the Settlement only, the Action is hereby preliminarily certified as a class action on behalf of the "Settlement Class," which is defined all those who purchased or otherwise acquired Amylyx securities between November 11, 2022, and November 8, 2023, inclusive, and who were damaged thereby. Excluded from the Settlement Class are Defendants; the officers and directors of Amylyx during the Settlement Class Period;

members of their immediate families and their legal representatives, heirs, agents, affiliates, successors or assigns; Defendants' liability insurance carriers, and any affiliates or subsidiaries thereof; any entity in which Defendants or their immediate families have or had a controlling interest during the Settlement Class Period; and those persons who exclude themselves by submitting a request for exclusion from the Settlement Class that is accepted by the Court.

5. Class Representatives and Class Counsel. Pursuant to Rule 23 of the Federal Rules of Civil Procedure, preliminarily and for the purposes of this Settlement only, Plaintiff is certified as the class representative on behalf of the Settlement Class ("Class Representative") and Lead Counsel, Pomerantz, LLP, previously selected by Lead Plaintiff and appointed by the United States District Court for the Southern District of New York, is hereby appointed as Lead Counsel for the Settlement Class ("Class Counsel").

6. Preliminary Findings Concerning Proposed Settlement. The Court preliminarily finds that the Settlement should be preliminarily approved as: (a) the result of good faith, arm's length negotiations; (b) falling within a range of reasonableness warranting final approval; and (c) sufficiently fair, reasonable, and adequate to the Settlement Class Members to warrant providing notice of the Settlement to Settlement Class Members and holding a Final Approval Hearing, as described below.

7. Final Approval Hearing. A hearing (the "Final Approval Hearing") pursuant to Federal Rule of Civil Procedure 23(e) will be held before the Honorable Nathaniel M. Gorton, Senior United States District Judge of the District of Massachusetts, Courtroom No. 4, 3rd Floor, 1 Courthouse Way, Boston, Massachusetts 02210, on _____ 20__ at __:___ .m. to, among other things: (a) determine whether to certify, for settlement purposes only, the Settlement Class; (b) determine whether the Settlement is fair, reasonable, and adequate, and warrants final

approval by the Court; (c) determine whether the Final Judgment substantially in the form of Exhibit B to the Settlement Stipulation should be entered; (d) determine whether the proposed Plan of Allocation for the distribution of the Net Settlement Fund is fair and reasonable and should be approved by the Court; (e) consider the application of Class Counsel for an award of attorneys' fees and expenses and an award to the Class Representative; (f) consider any objections received by the Court; and (g) rule upon such other matters as the Court may deem appropriate.

8. Continuance of Hearing/Modification of Settlement. The Court reserves the right to continue or adjourn the Final Approval Hearing to a later date without further notice to the Settlement Class, and to approve the Settlement with such modifications as may be agreed to by the Settling Parties without further notice to the Settlement Class where to do so would not impair Settlement Class Members' rights in a manner inconsistent with Rule 23 or due process of law. The Court further reserves the right to enter the Final Judgment or an Alternative Judgment regardless of whether, and to what extent, it has approved the Plan of Allocation or awarded attorneys' fees and expenses.

9. Notice. The Court approves the form, substance and requirements of (a) the Notice; (b) the Summary Notice; (c) the Post-Card Notice; and (d) the Proof of Claim and Release Form, all of which are exhibits to the Settlement Stipulation, and finds that the procedures for publication, mailing and distribution of such notices substantially in the manner set forth in Paragraph 10 below meet the requirements of due process, Rule 23 of the Federal Rules of Civil Procedure, and Section 21D(a)(7) of the Exchange Act, 15 U.S.C. §78u-4(a)(7), as amended by the Private Securities Litigation Reform Act of 1995, and all other applicable laws; constitute the best notice practicable under the circumstances; are reasonably calculated under the circumstances to describe the terms and effect of the Settlement and to apprise Settlement Class Members of their

right to object to the proposed Settlement or to exclude themselves from the Settlement Class; and constitute due and sufficient notice to all Persons entitled thereto. No Settlement Class Member will be relieved from the terms and conditions of the Settlement, including the releases provided pursuant thereto, based upon the contention or proof that such Settlement Class Member failed to receive actual or adequate notice.

10. Retention of Claims Administrator and Manner of Notice. Class Counsel is authorized to retain Strategic Claims Services as the Claims Administrator to supervise and administer the notice procedure as well as the processing of claims under the supervision of Class Counsel as more fully set forth below:

(a) Either:

i. Class Counsel, through the Claims Administrator, shall cause the Post-Card Notice, substantially in the form annexed to the Settlement Stipulation, to be e-mailed, at least ninety-four (94) calendar days prior to the Final Approval Hearing, to all Settlement Class Members who can be identified with reasonable effort and whose email addresses can also be so identified; or

ii. Class Counsel, through the Claims Administrator, shall cause the Post-Card Notice, substantially in the form annexed to the Settlement Stipulation, to be mailed, by first class mail, postage prepaid, at least ninety-four (94) calendar days prior to the Final Approval Hearing, to all Settlement Class Members who can be identified with reasonable effort but whose email addresses cannot be so identified.

(b) Class Counsel, through the Claims Administrator, shall cause the Settlement Stipulation and its exhibits, this Order, and a copy of the Notice and Proof of Claim and Release

Form to be posted on the Claims Administrator's website within sixteen (16) calendar days after entry of this Order.

(c) Class Counsel, through the Claims Administrator, shall cause the Summary Notice to be published electronically once on the GlobeNewswire and in print once in the Investor's Business Daily at least ninety-four (94) calendar days prior to the Final Approval Hearing.

11. Additional Provisions Concerning Notice. In order to effectuate providing notice as described above:

(a) The Escrow Agent may, without further approval from the Court, disburse at the direction of Class Counsel up to \$300,000 from the Settlement Fund for Administrative Costs, on the terms set forth in the Settlement Stipulation.

(b) No later than one hundred (100) calendar days prior to the Final Approval Hearing, Amylyx shall provide and/or cause its transfer agent to provide to Class Counsel a list of the record owners of Amylyx Pharmaceuticals, Inc. securities during the Settlement Class Period in a usable electronic format, such as an Excel spreadsheet. This information will be kept confidential and not used for any purpose other than to provide the notice contemplated by this Order.

(c) Class Counsel, through the Claims Administrator, shall take all reasonable efforts to give notice to nominees or custodians who held Amylyx Pharmaceuticals, Inc. securities during the Settlement Class Period as record owners but not as beneficial owners, preferably via email. Such nominees or custodians shall, within ten (10) calendar days of receipt of a notice, either (i) request the electronic version of the Post-Card Notice or the link to the electronic Notice and Proof of Claim from the Claims Administrator and, within ten (10) calendar days of receipt, email the electronic Post-Card Notice or the link to the electronic Notice and Proof of Claim to all such

beneficial owners for whom they are nominee or custodian and for whom valid email addresses are available; (ii) request copies of the Post-Card Notice from the Claims Administrator and, within (10) calendar days of receipt of those Post-Card Notices, mail the Post-Card Notice to all beneficial owners for whom they are nominee or custodian at the beneficial owners' last known addresses; or (iii) provide the Claims Administrator with lists of the names, last known addresses, and email addresses (to the extent known) of such beneficial owners, in which event the Claims Administrator shall promptly deliver the Post-Card Notice to such beneficial owners. Nominees or custodians who elect to send the PostCard Notice to their beneficial owners via email or regular mail shall send a written certification to the Claims Administrator confirming that the mailing has been made as directed. The Claims Administrator shall, if requested, reimburse nominees or custodians out of the Settlement Fund solely for their reasonable out-of-pocket expenses incurred in providing notice to beneficial owners, not to exceed \$0.02 per emailed link to the electronic Long Notice and Proof of Claim sent; \$0.02 per Post-Card Notice, plus postage at the current pre-sort rate used by the Claims Administrator, for Post-Card Notices actually mailed; or \$0.02 per beneficial owner record (consisting of name, address, and email address) provided to the Claims Administrator.

(d) Not later than thirty-four (34) calendar days before the Final Approval Hearing, Class Counsel shall file with the Court one or more affidavits (or declarations) showing timely compliance with the foregoing mailing or emailing and publication requirements.

12. Claims. In order to be entitled to participate in recovery from the Net Settlement Fund after the Effective Date, each Settlement Class Member shall take the following action and be subject to the following conditions:

(a) A properly completed and executed Proof of Claim and Release Form must be submitted to the Claims Administrator at the Post Office Box indicated in the Notice, postmarked no later than _____, 20__ (ten (10) calendar days prior to the Final Approval Hearing). Such deadline may be further extended by Order of the Court. Each Proof of Claim and Release Form shall be deemed to have been submitted when legibly postmarked (if properly addressed and mailed by first class mail), provided such Proof of Claim and Release Form is actually received before the filing of a motion for an Order of the Court approving distribution of the Net Settlement Fund. Any Proof of Claim and Release Form submitted in any other manner shall be deemed to have been submitted when it was actually received by the Claims Administrator at the address designated in the Notice.

(b) The Proof of Claim and Release Form submitted by each Settlement Class Member must satisfy the following conditions: (i) it must be properly completed, signed and submitted in a timely manner in accordance with the provisions of the preceding subparagraph; (ii) it must be accompanied by adequate supporting documentation for the transactions reported therein, in the form of broker confirmation slips, broker account statements, an authorized statement from the broker containing the transactional information found in a broker confirmation slip, or such other documentation as is deemed adequate by the Claims Administrator or Class Counsel; (iii) if the person executing the Proof of Claim and Release Form is acting in a representative capacity, a certification of his or her current authority to act on behalf of the Settlement Class Member must be provided with the Proof of Claim and Release Form; and (iv) the Proof of Claim and Release Form must be complete and contain no material deletions or modifications of any of the printed matter contained therein and must be signed under penalty of perjury.

13. Reviewing Claims. Once the Claims Administrator has considered a timely submitted Proof of Claim and Release Form, it shall determine whether such claim is valid, deficient, or rejected. For each claim determined to be either deficient or rejected, the Claims Administrator shall send a deficiency letter or rejection letter as appropriate, describing the basis on which the claim was so determined. Persons who timely submit a Proof of Claim and Release Form that is deemed deficient or otherwise rejected shall be afforded a reasonable time (at least ten (10) calendar days) to cure such deficiency if it shall appear that such deficiency may be cured. If any Settlement Class Member whose claim has been rejected in whole or in part wishes to contest such rejection, the Settlement Class Member must, within ten (10) calendar days after the date of mailing of the notice of rejection, serve upon the Claims Administrator a notice and statement of reasons indicating the Settlement Class Member's ground for contesting the rejection along with any supporting documentation, and requesting a review thereof by the Court. If an issue concerning a claim cannot be otherwise resolved, Class Counsel shall thereafter present the request for review to the Court. By submitting a Proof of Claim and Release Form, Settlement Class Members submit to the jurisdiction of the Court with respect to the claim submitted. No discovery shall be allowed on the merits of the Action or the Settlement in connection with processing of the Proofs of Claim, nor shall any discovery from or of Defendants be allowed on any topic. No dispute regarding a Proof of Claim and Release Form shall affect or delay the entry or finality of the Final Judgment or an Alternative Judgment.

14. Exclusions From the Settlement Class. Settlement Class Members shall be bound by all determinations and judgments in this Action, whether favorable or unfavorable, unless such Persons request exclusion from the Settlement Class in a timely and proper manner, as hereinafter provided. A Settlement Class Member wishing to make a request for exclusion shall mail it, in

written form, by first class mail, postage prepaid, or otherwise deliver it, so that it is received no later than _____, 20____ (thirty (30) calendar days prior to the Final Approval Hearing) (the “Exclusion Deadline”), to the address listed in the Notice. In order to be valid, such request for exclusion must (A) clearly indicate the name, address, phone number, and e-mail address of the Person seeking exclusion, and state that the sender specifically “requests to be excluded from the Settlement Class in *Shih v. Amylyx Pharmaceuticals, Inc. et al.*, 1:24-cv-12068-NMG (D. Mass.)”; and (B) state the date, number of shares and dollar amount of each Amylyx Pharmaceuticals, Inc. securities purchase, acquisition and sale during the Settlement Class Period, as well as the number of shares of Amylyx Pharmaceuticals, Inc. securities held by the Person as of November 11, 2022 and November 8, 2023 (the first and last days of the Settlement Class Period). Any such request for exclusion must be signed and submitted by the beneficial owner under penalty of perjury. The request for exclusion shall not be effective unless it provides the required information, is legible, and is made within the time stated above, or the exclusion is otherwise accepted by the Court. Class Counsel may contact any Person filing a request for exclusion, or their attorney if one is designated, to discuss the exclusion. The Claims Administrator shall provide all requests for exclusion and supporting documentation submitted therewith (including untimely requests) to counsel for the Settling Parties as soon as possible and no later than the Exclusion Deadline or upon the receipt thereof (if later than the Exclusion Deadline).

15. Revoking Requests for Exclusion. Any Person that submits a request for exclusion may thereafter submit to the Claims Administrator and to Class Counsel a written and signed revocation of that request for exclusion, provided that it is received no later than two (2) Business

Days before the Final Approval Hearing, in which event that Person will be included in the Settlement Class.

16. Objections to Settlement. The Court will consider objections to the Settlement, the Plan of Allocation, or the Fee and Expense Application, provided, however, that no Settlement Class Member or other Person shall be heard or entitled to contest the approval of the terms and conditions of the proposed Settlement or, if approved, the Final Judgment, or any other order relating thereto, unless that Person has served copies of any objections, papers, and briefs to each of the following counsel at least seventeen (17) calendar days prior to the Final Approval Hearing Date:

Class Counsel

POMERANTZ LLP
Jeremy A. Lieberman
Samantha Daniels
600 Third Avenue, 20th Floor
New York, New York 10016
Telephone: (212) 661-1100
Facsimile: (917) 463-1044
jalieberman@pomlaw.com
sdaniels@pomlaw.com

Counsel for Defendants

GOODWIN PROCTER LLP
Caroline H. Bullerjahn
100 Northern Avenue
Boston, MA 02210
Tel.: 617-570-1000
Fax: 617-523-1231
cbullerjahn@goodwinlaw.com

Class Counsel will file with the Court all objections it receives. To be valid, an objection must contain (1) the objector's name, address, telephone number, and email address; (2) a statement that the objector is objecting to the proposed Settlement, Plan of Allocation, and/or the award of attorneys' fees and expenses and award to Plaintiff in *Shih v. Amylyx Pharmaceuticals*,

Inc. et al., 1:24-cv-12068-NMG (D. Mass.); (3) documentation of all purchases and sales of Amylyx Pharmaceuticals, Inc. securities during the Settlement Class Period; (4) all grounds for the objection, including any legal support known to the Settlement Class Member and/or his, her, or its counsel; (5) the name, address and telephone number of all counsel who represent the Settlement Class Member, including former or current counsel who may be entitled to compensation in connection with the objection; and (6) the number of times the Settlement Class Member and/or his, her, or its counsel has filed an objection to a class action settlement in the last five years, the nature of each such objection in each case, the jurisdiction in each case, and the name of the issuer of the security or seller of the product or service at issue in each case.

17. Appearance at the Final Approval Hearing. Attendance at the Final Approval Hearing is not necessary, but Persons wishing to be heard orally in opposition to the approval of the Settlement Stipulation, the Plan of Allocation, and/or the Fee and Expense Application are required to indicate in their written objection (or in a separate writing submitted to the counsel listed in Paragraph 16 no later than seventeen (17) days prior to the Final Approval Hearing) that they intend to appear at the Final Approval Hearing and identify any witnesses they may call to testify and exhibits they intend to introduce into evidence at the Final Approval Hearing. Objectors or their attorneys intending to appear at the Final Approval Hearing must also, no later than seventeen (17) days prior to the Final Approval Hearing, file with the Court, and serve upon counsel listed in the above paragraph, a notice of intention to appear, setting forth the name and address of anyone intending to appear. Any objector or counsel who does not timely file and serve a notice of intention to appear in accordance with this paragraph shall not be permitted to appear, except for good cause shown. Settlement Class Members do not need to appear at the Final Approval Hearing or take any other action to indicate their approval.

18. Waiver of Objections. Any Settlement Class Member who does not object in the manner prescribed above shall be deemed to have waived all such objections and shall forever be foreclosed from making any objection to the fairness, adequacy or reasonableness of the Settlement, the Final Judgment to be entered approving the Settlement, the Plan of Allocation, and/or the Fee and Expense Application, unless otherwise ordered by the Court; shall be bound by all the terms and provisions of the Settlement Stipulation and by all proceedings, orders and judgments in the Action, including but not limited to the Final Judgment and all releases therein; and shall also be foreclosed from appealing from any judgment or order entered in this Action.

19. Adjournment. The Court reserves the right to adjourn the Final Approval Hearing without any further notice other than entry of an Order on the Court's docket, and to approve the Settlement without further notice to the Settlement Class.

20. Papers in Support of Final Settlement Approval. All papers in support of the Settlement, the Plan of Allocation and/or the Fee and Expense Application shall be filed and served no later than thirty-four (34) calendar days before the Final Approval Hearing. Any submissions filed in response to any objections or in further support of the Settlement, the Plan of Allocation and/or the Fee and Expense Application shall be filed no later than seven (7) calendar days prior to the Final Approval Hearing. Defendants, their counsel, their insurers and other Released Parties shall have no responsibility for the Plan of Allocation or any application for attorneys' fees or expenses or Award to Plaintiff submitted by Class Counsel, and such matters will be considered separately from the fairness, reasonableness, and adequacy of the Settlement. No order or proceedings relating to the Plan of Allocation or any application for attorneys' fees or expenses or Award to Plaintiff shall affect or delay the entry or finality of any order granting final approval to the Settlement.

21. Bar on Litigating Released Claims. Pending final determination of whether the Settlement should be approved, all Releasing Parties and anyone who acts or purports to act on their behalf shall be enjoined from instituting, continuing, asserting or prosecuting, or assisting any Person in instituting, continuing, asserting or prosecuting in any forum, any Released Claim, in any capacity, against any Released Party. Unless and until the Settlement Stipulation is cancelled and terminated pursuant to the Settlement Stipulation, all proceedings in the Action, other than such proceedings as may be necessary to carry out the terms and conditions of the Settlement Stipulation, are hereby stayed and suspended until further order of the Court.

22. Funds in Custody of Court. All funds held by the Escrow Agent shall be deemed and considered to be in the custody of the Court, and shall remain subject to the jurisdiction of the Court, until such time as such funds shall be distributed or returned pursuant to the Settlement Stipulation, the Plan of Allocation and/or further order(s) of the Court.

23. Use of Settlement Stipulation and Related Materials. Neither the Settlement Stipulation, nor any of its terms or provisions, nor any of the negotiations or proceedings connected with it, nor this Order, shall be construed as an admission or concession by Defendants, their counsel, their insurers or any of the other Released Parties of the truth of any of the allegations in the Action, or of any liability, fault, or wrongdoing of any kind, and shall not be construed as, or deemed to be evidence of or an admission or concession that Plaintiff or any Settlement Class Members have suffered any damages, harm, or loss. Further, neither the Settlement Stipulation, nor any of its terms or provisions, nor any of the negotiations or proceedings connected with it, nor this Order shall be construed as an admission or concession by Plaintiff of the validity of any factual or legal defense or of the infirmity of any of the claims or facts alleged in this Action.

24. Termination of Settlement. In the event the Settlement is not consummated in accordance with the terms of the Settlement Stipulation, then this Order (including any amendment(s) thereof) shall be null and void, of no further force or effect, and without prejudice to any Settling Party, and may not be introduced as evidence or used in any action or proceeding by any Person against the Settling Parties or the Released Parties. In such event, Paragraph 10.6 of the Settlement Stipulation shall govern the rights of the Settling Parties.

25. Retention of Jurisdiction. The Court retains exclusive jurisdiction over the Action to consider all further matters arising out of, or relating to, the Settlement Stipulation, including by way of illustration and not limitation, any dispute concerning any Proof of Claim and Release Form submitted and any future requests by one or more of the Parties that the Final Judgment be enforced.

Dated: _____, 20__

HON. NATHANIEL M. GORTON
SENIOR UNITED STATES DISTRICT JUDGE
United States District Court
District of Massachusetts

**UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS**

OLIVER SHIH, Individually and on Behalf of
All Others Similarly Situated,

Plaintiff, v.

AMYLYX PHARMACEUTICALS, INC.,
JOSHUA B. COHEN, JUSTIN B. KLEE,
JAMES M. FRATES, and MARGARET
OLINGER,

Defendants.

Case No. 1:24-cv-12068-NMG

NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION

Please be advised that your rights may be affected by the above-captioned securities class action (the “Action”) pending in the United States District Court for the District of Massachusetts (the “Court”) if you purchased or otherwise acquired Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) securities during the period from November 11, 2022, through November 8, 2023, inclusive (the “Settlement Class Period”), and were allegedly damaged thereby (the “Settlement Class”).¹

A federal court authorized this Notice. This is not attorney advertising.

- The Court will hold a hearing on ____, 2026 at ____ :__ __.m. to decide whether to approve the Settlement (the “Final Approval Hearing”). If approved by the Court, the Settlement will provide for the payment of \$6,500,000 gross (the “Settlement Amount”), plus interest as it accrues, minus attorneys’ fees, expenses, compensatory award to Plaintiff, Administrative Costs, and Taxes on interest, to persons and entities who purchased Amylyx securities (NASDAQ ticker symbol: AMLX) during the Settlement Class Period, and who submit eligible Proof of Claim and Release Forms (“Proof of Claim”).
- Based on Plaintiff’s consulting damages expert’s estimate that approximately 27.1 million Amylyx shares have been affected by the conduct alleged in the Action, and assuming that all Settlement Class Members elect to participate in the Settlement, the estimated average gross recovery (before the deduction of any Court-approved fees, expenses and costs as described herein) is approximately \$.24 per share of Amylyx securities. Settlement Class Members should note, however, that the foregoing average recovery is only an estimate. Settlement Class Members may recover more or less than this amount depending on, among other factors, when their shares were purchased or otherwise acquired and the price at the time of purchase or acquisition; whether the shares were sold and, if so, when they were sold and for how much; and the aggregate value of the Recognized Losses represented by valid and acceptable Proof

¹ All capitalized terms used in this Notice that are not otherwise defined herein have the meanings given to them in the Stipulation of Settlement, dated May 4, 2026 (the “Stipulation”), which is available at www.strategicclaims.net/Amylyx/.

of Claim forms. In addition, the actual recovery of Settlement Class Members may be further reduced by the payment of fees and costs from the Settlement Fund, as approved by the Court. Distributions to Settlement Class Members will be made based on the Plan of Allocation set forth below (*see* pages 11-14 below) or such other plan of allocation as may be approved by the Court.

- Attorneys for Plaintiff and the Settlement Class, Pomerantz LLP (“Lead Counsel”), intend to ask the Court to award them fees of up to one-third (33 $\frac{1}{3}$ %) of the Settlement Amount, plus interest, and payment of up to \$100,000 in litigation expenses, plus interest, and up to \$5,000 in total in compensatory award to Plaintiff, pursuant to the Private Securities Action Reform Act of 1995 (“PSLRA”). Since the Action’s inception, Lead Counsel have expended considerable time and effort in this case on a contingent-fee basis and have advanced the expenses of the litigation with the expectation that if they were successful in obtaining a recovery for the Settlement Class, they would be paid from such recovery. Collectively, the requested attorneys’ fees, litigation expenses and compensatory award to Plaintiff are estimated to average approximately \$.08 per share of Amylyx securities. If approved by the Court, these amounts will be paid from the Settlement Fund.
- The estimated average net recovery, after the deductions set forth in the preceding paragraph, is approximately \$.16 per share. These estimates are based on the assumptions set forth in the preceding paragraphs. Your actual recovery, if any, will depend on, among other things, when your shares were purchased or otherwise acquired and the price at the time of purchase or acquisition; whether the shares were sold and, if so, when they were sold and for how much; and the aggregate value of the Recognized Losses represented by valid and acceptable Proof of Claim forms.
- The Settlement resolves the Action and Plaintiff’s claims that Amylyx, Joshua B. Cohen, Justin B. Klee, James M. Frates, and Margaret Olinger (collectively, “Defendants”) violated federal securities laws by allegedly making misrepresentations and/or omissions of material fact in public statements to the investing public. Defendants have denied and continue to deny each, any, and all allegations of wrongdoing, fault, liability, or damage whatsoever asserted by Plaintiff.
- The Parties disagree on how much money, if any, could have been won if Plaintiff prevailed on each of his claims.
- For Plaintiff, the principal reason for the Settlement is the guaranteed cash benefit to the Settlement Class. This benefit must be assessed in light of the risk of the uncertain outcome and the risk of any litigation. The Defendants deny that the claims advanced in the Action are meritorious, deny that they have any liability whatsoever to Plaintiff or to any Settlement Class Member, and by entering into this proposed Settlement do not concede the merit of any claims or the lack of merit of any defense to liability. The Defendants have agreed to enter into this proposed Settlement solely to avoid the expense, distraction, time, and uncertainty associated with continuing litigation of the Action.
- If you are a member of the Settlement Class, your legal rights will be affected whether you act or do not act. If you do not act, you may permanently forfeit your right to recover on these claims. Therefore, you should read this Notice carefully.

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT

SUBMIT A CLAIM FORM	The only way to get a payment from the Settlement. Proof of Claim forms must be postmarked or submitted online on or before ____ , 2026
EXCLUDE YOURSELF	Get no payment. This is the only option that allows you to ever be part of any other lawsuit against the Defendants or any other Released Parties about the legal claims that were or could have been asserted in this case. Requests for exclusion must be received on or before ____ , 2026
OBJECT	Write to the Court about why you do not like the Settlement, the Plan of Allocation, and/or the request for attorneys' fees, costs, and expenses. You will still be a member of the Settlement Class. Objections must be received by the Court and counsel on or before ____ , 2026
PARTICIPATE IN THE HEARING	Ask to speak in Court about the fairness of the Settlement, the Plan of Allocation, and/or the request for attorneys' fees, costs, and expenses. Requests to speak must be received by the Court and counsel on or before ____ , 2026
DO NOTHING	Get no payment. Give up your rights.

INQUIRIES

Please do not contact the Court, Defendants, Defendants' Counsel, or the Office of the Clerk of Court regarding this Notice. All inquiries concerning this Notice, the Proof of Claim form, or any other questions by Settlement Class Members should be directed to:

Amylyx Pharmaceuticals, Inc.
Securities Settlement
 c/o Strategic Claims Services
 600 N. Jackson Street, Suite 205
 P.O. Box 230
 Media, PA 19063
 Telephone: (866) 274-4004
 Facsimile: (610) 565-7985
 info@strategicclaims.net

or

Jeremy A. Lieberman, Esq.
 Samantha Daniels, Esq.
 POMERANTZ LLP
 600 Third Ave, Floor 20
 New York, NY 10016
 Telephone: (212) 661-1100
 Facsimile: (917) 463-1044
 jalieberman@pomlaw.com
 sdaniels@pomlaw.com

BASIC INFORMATION CONCERNING THE SETTLEMENT

1. Why did I receive notice of the Settlement?

You or someone in your family may have purchased or otherwise acquired Amylyx securities during the period from November 11, 2022, through November 8, 2023, inclusive (the "Settlement Class Period"). **Receipt of notice does not mean that you are a member of the Settlement Class or that you will be entitled to receive a payment.** If you wish to be eligible for a payment, you are required to submit the Proof of Claim form that is being distributed with this Notice. *See* Question 10 below.

2. What is this case about?

The proposed Settlement resolves the Action known as *Shih v. Amylyx Pharmaceuticals, Inc., et al.*, Case No. 1:24-cv-12068-NMG (D. Mass.). The Court in charge of the case is the United States District Court for the District of Massachusetts. The Action involves allegations that Defendants violated the Securities Exchange Act of 1934 (“Exchange Act”). The operative Amended Class Action Complaint alleges that Defendants made materially false and misleading statements about the success of the launch of AMX0035 (commercially referred to as “Relyvrio” in the U.S.), for the treatment of ALS in adults in the U.S, which artificially inflated the price of Amylyx securities during the Settlement Class Period, and that, when the true facts were revealed, these disclosures caused the price of Amylyx securities to drop, causing harm to members of the Settlement Class.

3. Why is this a class action?

In a class action, one or more persons, called “plaintiffs”, sue on behalf of all persons who have similar claims. All of the persons with similar claims are referred to as a “class”. One court resolves the issues for all class members, except for those who exclude themselves from the class.

4. Why is there a settlement?

Plaintiff and the Defendants do not agree about the merits of Plaintiff’s allegations and the Defendants’ defenses with respect to liability or the average amount of damages per share, if any, that would be recoverable if Plaintiff was to prevail at trial on each claim. The issues on which Plaintiff and the Defendants disagree include: (1) whether the challenged statements were materially false or misleading or otherwise actionable under federal securities laws; (2) whether the Defendants acted with scienter; (3) whether Defendants’ alleged misstatements and omissions caused any damages to investors; (4) the amount of alleged damages, if any, that could be recovered at trial.

This matter has not gone to trial, and the Court has not decided in favor of either Plaintiff or Defendants. Instead, Plaintiff and Defendants have agreed to settle the case. Plaintiff and Lead Counsel believe the Settlement is best for all Settlement Class Members because of the expense and length of continued proceedings necessary to prosecute the Action against Defendants through trial and appeals, as well as the uncertain outcome and the risk of any litigation. Defendants continue to deny each and all of the claims and contentions alleged by Plaintiff and are entering into the Stipulation solely to eliminate the uncertainty, distraction, burden, and expense of further litigation and the length of continued proceedings necessary to defend the Action through trial and appeals.

WHO IS IN THE SETTLEMENT

To see if you will get money from this Settlement, you first have to determine if you are a Settlement Class Member.

5. How do I know if I am part of the Settlement Class?

The Settlement Class consists of all those who purchased or otherwise acquired Amylyx securities between November 11, 2022, and November 8, 2023, inclusive, and who were damaged thereby.

Check your investment records or contact your broker to see if you have any eligible securities. The Parties do not independently have access to your trading information.

6. Are there exceptions to being included?

Yes. Excluded from the Settlement Class are: Defendants; the officers and directors of Amylyx who served in their roles between November 11, 2022 and November 8, 2023; members of their immediate families and their legal representatives, heirs, agents, affiliates, successors or assigns; Defendants' liability insurance carriers, and any affiliates or subsidiaries thereof; any entity in which Defendants or their immediate families have or had a controlling interest between November 11, 2022 and November 8, 2023. Also excluded from the Settlement Class are any persons or entities who or which exclude themselves by submitting a request for exclusion that is accepted by the Court.

7. What if I am still not sure if I am included?

If you are still not sure whether you are included, you can ask for free help. You can contact the Claims Administrator toll-free at (866) 274-4004 or by email at info@strategicclaims.net or by visiting the website www.strategicclaims.net/Amylyx/, or you can fill out and return the Proof of Claim form available at www.strategicclaims.net/Amylyx/, to see if you qualify.

THE SETTLEMENT BENEFITS – WHAT YOU GET**8. What does the Settlement provide?**

The proposed Settlement provides for Defendants to cause the payment of \$6,500,000 into a settlement fund, which may accrue interest (the "Settlement Fund"). The Settlement is subject to Court approval. Also, subject to the Court's approval, a portion of the Settlement Fund will be used to pay attorneys' fees with interest and reasonable litigation expenses to Lead Counsel and compensatory awards to Plaintiff. A portion of the Settlement Fund also will be used to pay Taxes due on interest earned by the Settlement Fund, if necessary, and the costs of the claims administration, including the costs of printing and mailing the Postcard Notice, the costs of publishing notice, and the costs of processing claims. After the foregoing deductions from the Settlement Fund have been made, the amount remaining (the "Net Settlement Fund") will be distributed to Settlement Class Members who submit timely, valid claims, according to the Plan of Allocation to be approved by the Court ("Authorized Claimants").

9. How much will my payment be?

Your share of the Net Settlement Fund will depend on several factors, including (i) the date(s) on which you purchased or otherwise acquired Amylyx securities, and the price(s) at the time(s) of purchase or acquisition; (ii) whether you sold Amylyx securities, and if so, the date(s) and price(s) of any such sales; (iii) the Recognized Losses of timely and valid claims submitted by other Settlement Class Members; (iv) the amount of administrative costs, including the costs of notice; and (v) the amount awarded by the Court to Lead Counsel for attorneys' fees and expenses, and any compensatory award to Plaintiff.

The Claims Administrator will determine each Authorized Claimant's *pro rata* share of the Net Settlement Fund based upon each Authorized Claimant's Recognized Loss calculated pursuant to the allocation formulas set forth in the Plan of Allocation approved by the Court. The allocation formula is the basis upon which the Net Settlement Fund will be proportionately allocated to Settlement Class Members with valid claims. The allocation formulas are not intended to estimate the amount that a Settlement Class Member might have been able to recover after a trial; they also

are not an estimate of the amount that will be paid to Authorized Claimants pursuant to the Settlement. You can calculate your Recognized Loss by following the instructions in the proposed Plan of Allocation at pages 11-14 of this Notice.

It is unlikely that you will get a payment for all of your Recognized Loss. After all Settlement Class Members have sent in their Proof of Claim forms, the payment you get will be a share of the Net Settlement Fund equal to your proportional share of the Recognized Losses of timely and valid claims submitted by all Authorized Claimants.

HOW YOU GET A PAYMENT—SUBMITTING A CLAIM FORM

10. How can I get a payment?

To qualify for a payment, you must submit a Proof of Claim and Release Form. A copy of the Proof of Claim and Release Form (“Proof of Claim”) is enclosed with this Notice. The Proof of Claim form may also be downloaded from the website for the Settlement, www.strategicclaims.net/Amylyx/, or submitted online using the website claim portal. Read the instructions carefully, fill out the form, include all the documents that the form requests, sign it, and mail or submit it online so that it is postmarked or received **no later than 11:59 p.m. ET on _____, 2026**. The Proof of Claim may be submitted online at www.strategicclaims.net/Amylyx/ or mailed to:

Amylyx Pharmaceuticals, Inc. Securities Litigation
c/o Strategic Claims Services
600 N. Jackson Street, Suite 205
P.O. Box 230
Media, PA 19063
Fax: (610) 565-7985
info@strategicclaims.net

The Claims Administrator will process your claim and determine whether you are an Authorized Claimant.

11. When would I get my payment?

The Court will hold a Final Approval Hearing on _____, 2026 at _____ to decide whether to approve the Settlement. If the Court approves the Settlement, there might be appeals afterwards. It is always uncertain whether these appeals can be resolved, and resolving them can take time, perhaps more than a year. It also takes time for all Proof of Claim forms to be processed. Please be patient.

12. What am I giving up to get a payment or to stay in the Settlement Class?

Unless you timely exclude yourself, you will remain a Settlement Class Member and will be bound by the release of claims against the Defendants and the Released Parties. That means you cannot sue, continue to sue, or be part of any other lawsuit against the Defendants or the Released Parties about the Released Claims in this Action. It also means that all of the Court’s orders will apply to you and legally bind you, and you will release your claims in this Action against the Defendants and the Released Parties. The specific terms of the release are included in the Stipulation, which is available at www.strategicclaims.net/Amylyx/.

EXCLUDING YOURSELF FROM THE SETTLEMENT CLASS

If you do not want a payment from this Settlement, and you want to keep any right you may have to sue or continue to sue Defendants and the other Released Parties on your own about the claims being released in this Settlement, then you must take steps to remove yourself from the Settlement Class. This is called excluding yourself, or “opting out,” from the Settlement Class. Defendants can terminate the Settlement if a certain amount of exclusion requests is received.

13. How do I get out of the proposed Settlement?

To exclude yourself from the Settlement Class, you must mail a letter stating that you request to be “excluded from the Settlement Class in *Shih v. Amylyx Pharmaceuticals, Inc., et al.*, Case No. 1:24-cv-12068-NMG (D. Mass.)” To be valid, the letter must state (A) your name, address, telephone number, and email address (if any); and (B) the number of shares of Amylyx securities that you (i) owned as of the opening of trading on November 10, 2022 and the close of trading on November 8, 2023, and (ii) purchased, acquired, and/or sold between November 11, 2022 and November 8, 2023, inclusive, as well as the dates and prices for each such purchase, acquisition, and sale. In order to be valid, a request for exclusion must be submitted with documentary proof of such ownership and such purchase, acquisition, and/or sale transactions. Any request for exclusion must be signed and submitted by you, as the beneficial owner. You must submit your exclusion request so that it is **received no later than _____, 2026 at:**

Amylyx Pharmaceuticals, Inc. Securities Litigation - EXCLUSIONS
c/o Strategic Claims Services
600 N. Jackson Street, Suite 205
P.O. Box 230
Media, PA 19063

You cannot exclude yourself by telephone or by email. If you properly exclude yourself, you will not receive a payment from the Net Settlement Fund, you cannot object to the Settlement, and you will not be legally bound by any orders or the Final Judgment in this case.

14. If I do not exclude myself, can I sue the Defendants or the other Released Parties for the same thing later?

No. Unless you exclude yourself by following the instructions above, you give up any rights to sue the Defendants or the other Released Parties for the claims being released in this Settlement. If you have a pending lawsuit against the Released Parties or related to any Released Claims, speak to your lawyer in that case immediately, since you must exclude yourself from this Settlement Class to continue your own lawsuit. Remember, the exclusion deadline is _____, 2026.

15. If I exclude myself, can I get money from the proposed Settlement?

No. If you exclude yourself, you may not send in a Proof of Claim form to ask for any money from this Settlement.

THE LAWYERS REPRESENTING YOU

16. Do I have a lawyer in this case?

The Court has appointed Pomerantz LLP as Lead Counsel to the Settlement Class, to represent you and the other Settlement Class Members. If you want to be represented by your own lawyer, you may hire one at your own expense and they may file a notice of appearance in the Action. Contact information for Pomerantz LLP is provided above.

17. How will the lawyers be paid?

Lead Counsel have expended considerable time litigating this Action on a contingent-fee basis and have paid for the expenses of the case themselves. They have not been paid attorneys' fees or for their expenses in advance of this Settlement. Lead Counsel have done so with the expectation that, if they are successful in recovering money for the Settlement Class, they will receive attorneys' fees and be paid for their litigation expenses from the Settlement Fund, as is customary in this type of litigation. Lead Counsel will not receive attorneys' fees or be paid for their litigation expenses except from the Settlement Fund. Therefore, Lead Counsel will file a motion prior to the Final Approval Hearing asking the Court for an award of attorneys' fees in an amount not greater than one-third (33⅓%) of the Settlement Fund and payment of litigation expenses of no more than \$100,000, plus interest on such fees and expenses, and for a compensatory award to Plaintiff of no more than \$5,000 in total. The Court may award less than these amounts. Any amounts awarded by the Court will come out of the Settlement Fund.

OBJECTING TO THE SETTLEMENT

18. How do I tell the Court that I object to the proposed Settlement, the Fee and Expense Application, and/or the Plan of Allocation?

If you are a Settlement Class Member, you can tell the Court you do not agree with the proposed Settlement, any part of the Settlement, the proposed Plan of Allocation, and/or Lead Counsel's motion for attorneys' fees and expenses and application for a compensatory award to Plaintiff. You can write to the Court setting out your objection. The Court will consider your views.

To object, you must send a signed letter saying that you object to the proposed Settlement, Plan of Allocation, and/or application for attorneys' fees and litigation expenses and award to Plaintiff in "*Shih v. Amylyx Pharmaceuticals, Inc., et al.*, Case No. 1:24-cv-12068-NMG (D. Mass.)." You must include (1) your name, address, telephone number, email address (if any), and your signature; (2) documentation of all purchases and sales of Amylyx securities during the Settlement Class Period; (3) the objection(s) and the specific reasons for each objection, including whether it applies only to you, to a specific subset of the Settlement Class, or to the entire Settlement Class, and any legal and evidentiary support, and witnesses you wish to bring to the Court's attention; (4) if you are represented by counsel, the name, address, and telephone number of all counsel, if any, who represent you, including your former or current counsel who may be entitled to compensation in connection with the objection; and (5) the number of times you and your counsel has filed an objection to a class action settlement in the last five years; the nature of each such objection in each case; and the name of the issuer of the security or seller of the product or service at issue in each case.

Attendance at the Final Approval Hearing is not necessary. Objectors wishing to be heard orally at the Final Approval Hearing must indicate in their written objection (or in a separate writing submitted to the counsel listed below no later than seventeen (17) days prior to the Final Approval Hearing) that they intend to participate in the Final Approval Hearing and identify any witnesses they may call to testify or exhibits they intend to introduce into evidence at the Final Approval Hearing. Objectors or their attorneys intending to appear at the Final Approval Hearing must also, no later than seventeen (17) days prior to the Final Approval Hearing, file with the Court, and serve upon counsel listed below, a notice of intention to appear, setting forth the name and address of anyone intending to appear. Any objector or counsel who does not timely file and serve a notice of intention to appear in accordance with this paragraph shall not be permitted to appear, except for good cause shown.

All written objections, papers, and briefs must be submitted to Lead Counsel and Defendants' Counsel at the addresses below such that they are **received no later than _____, 2026:**

<p>Lead Counsel Jeremy A. Lieberman Samantha Daniels, Esq. POMERANTZ LLP 600 Third Avenue, Floor 20 New York, NY 10016 Telephone: (212) 661-1100 Facsimile: (917) 463-1044 jalieberman@pomlaw.com sdaniels@pomlaw.com</p>	<p>Defendants' Counsel Caroline H. Bullerjahn, Esq. GOODWIN PROCTER LLP 100 Northern Avenue Boston, MA 02210 Tel.: 617-570-1000 Fax: 617-523-1231 cbullerjahn@goodwinlaw.com</p>
---	--

Lead Counsel will file all objections they receive with the Court.

19. What is the difference between objecting and excluding myself?

Objecting is telling the Court you do not like something about the Settlement or some part of it. You can object only if you stay in the Settlement Class. Requesting exclusion is telling the Court you do not want to be part of the Settlement Class or the Settlement. If you exclude yourself, you cannot object to the Settlement because it no longer concerns you. If you stay in the Settlement Class and object, but your objection is overruled, you will not be allowed a second opportunity to exclude yourself.

THE COURT'S FINAL APPROVAL HEARING

The Court will hold a hearing to decide whether to approve the proposed Settlement, the Fee and Expense Application, and the Plan of Allocation. You may participate, and you may ask to speak, but you do not have to.

20. When and where will the Court decide whether to approve the proposed Settlement?

The Court will hold a Final Approval Hearing, either in person or remotely at the Court's discretion, on _____, 2026 at _____ .m. at the United States District Court for the District of Massachusetts, John Joseph Moakely United States Courthouse, 1 Courthouse Way, 2nd Floor, Suite 2300, Boston, MA 02210.

At this hearing, the Court will consider whether the proposed Settlement is fair, reasonable, and adequate and should be approved by the Court; whether a Judgment as provided for in the Stipulation should be entered; and whether the proposed Plan of Allocation should be approved. If there are objections, the Court will consider them, and the Court will listen to people who have asked to speak at the hearing. The Court may also decide how much should be awarded to Lead Counsel for attorneys' fees and expenses and compensatory award to Plaintiff for his service in representing the Settlement Class.

We do not know how long these decisions will take. You should be aware that the Court may change the date and time of the Final Approval Hearing, or decide to hold it remotely, without another notice being mailed to Settlement Class Members. If you want to attend the hearing, you should check with Lead Counsel or on the Settlement website, www.strategicclaims.net/Amylyx/, beforehand to be sure that the date and/or time has not changed. The Claims Administrator will update the Settlement website in the event that the time or location of the Final Approval Hearing changes.

21. Do I have to come to the hearing?

No. Lead Counsel will answer any questions the Court may have. However, you are welcome to attend at your own expense. If you send an objection, you do not have to come to Court to talk about it. As long as you mail your written objection on time, the Court will consider it. You may also pay your own lawyer to attend, but it is not necessary. Settlement Class Members do not need to appear at the hearing or take any other action to indicate their approval.

22. May I speak at the hearing?

If you object, you may ask the Court for permission to speak at the Final approval Hearing. To do so, you must include with your objection (see question 18 above) a statement that you "intend to appear in *Shih v. Amylyx Pharmaceuticals, Inc., et al.*, Case No. 1:24-cv-12068-NMG (D. Mass.)." Persons who intend to object to the Settlement, the Plan of Allocation, and/or the application for an award of attorneys' fees, costs, and expenses, and desire to present evidence at the Final Approval Hearing, must include in their written objection the identity of any witnesses they may call to testify and exhibits they intend to introduce into evidence at the Final Approval Hearing. You cannot speak at the hearing if you exclude yourself.

IF YOU DO NOTHING

23. What happens if I do nothing at all?

If you do nothing, you will not receive a payment from the Settlement. However, unless you submit a request for exclusion in accordance with the instructions in the answer to question 13 above, you will not be able to start a lawsuit, continue with a lawsuit, or be part of any other lawsuit against Defendants or the Released Parties about the Released Claims (as defined in the Stipulation) ever again.

GETTING MORE INFORMATION

24. How do I get more information about the case?

This Notice contains only a summary of the terms of the proposed Settlement. For the precise terms and conditions of the proposed Settlement, please see the Stipulation, which is available by visiting the Settlement website at www.strategicclaims.net/Amylyx/ or by contacting the Claims Administrator toll-free at (866) 274-4004. More information about the matters involved in the Action—including, among other documents, the Preliminary Approval Order and the Proof of Claim form—is available at www.strategicclaims.net/Amylyx/. For even more detailed information concerning the matters involved in this Action, see the pleadings filed in the case, the papers filed in support of the Settlement and the Fee and Expense Application, and the orders entered by the Court, which are available for review during business hours at the Office of the Clerk of the Court, United States District Court, District of Massachusetts, John Joseph Moakely United States Courthouse, 1 Courthouse Way, Boston, MA 02210. (Please check the Court's website, www.nysd.uscourts.gov, for information about Court closures before visiting.) Subscribers to PACER, a fee-based service, can also view the papers filed publicly in the Action through the Court's on-line Case Management/Electronic Case Files system at <https://www.pacer.gov>.

PROPOSED PLAN OF ALLOCATION OF THE NET SETTLEMENT FUND

The Plan of Allocation is a matter separate and apart from the proposed Settlement, and any decision by the Court concerning the Plan of Allocation shall not affect the validity or finality of the proposed Settlement. The Court may approve the Plan of Allocation with or without modifications agreed to among the Parties, or another plan of allocation, without further notice to Settlement Class Members. Any orders regarding a modification of the Plan of Allocation will be posted to the Claims Administrator's website, www.strategicclaims.net/Amylyx/.

The Claims Administrator shall determine the *pro rata* share of the Net Settlement Fund of each Authorized Claimant based upon each Authorized Claimant's Recognized Loss. **Please Note:** The Recognized Loss formula, set forth below, is not intended to be an estimate of the amount of what a Settlement Class Member might have been able to recover after a trial, nor is it an estimate of the amount that will be paid to Authorized Claimants pursuant to the Settlement. The Recognized Loss formula is the basis upon which the Net Settlement Fund will be proportionately allocated to the Authorized Claimants. To the extent there are sufficient funds in the Net Settlement Fund, each Authorized Claimant will receive an amount equal to the Authorized Claimant's Recognized Loss and subject to the provisions in the following paragraphs. If, however, the amount in the Net Settlement Fund is not sufficient to permit payment of the total Recognized Loss of each Authorized Claimant, then each Authorized Claimant shall be paid the percentage of the Net Settlement Fund that each Authorized Claimant's Recognized Loss bears to the total Recognized Losses of all Authorized Claimants and subject to the provisions in the following paragraphs (*i.e.*, "*pro rata* share"). Payment in this manner shall be deemed conclusive against all Authorized Claimants. No distribution will be made on a claim where the potential distribution amount is less than ten dollars (\$10.00) in cash.

If any funds remain in the Net Settlement Fund by reason of uncashed checks, or otherwise, after the Claims Administrator has made reasonable and diligent efforts to have Authorized Claimants who are entitled to participate in the distribution of the Net Settlement Fund cash their distribution checks, then any balance remaining in the Net Settlement Fund six (6) months after the initial distribution of such funds shall be used: (i) first, to pay any amounts mistakenly omitted from the initial distribution to Authorized Claimants; (ii) second, to pay any additional Notice and Administration Costs incurred in administering the Settlement; and (iii) finally, to make a second distribution to Authorized Claimants who cashed their checks from the initial distribution and who would receive at least \$10.00 from such second distribution, after payment of the estimated costs or fees to be incurred in administering the Net Settlement Fund and in making this second distribution, if such second distribution is economically feasible. If six (6) months after such second distribution, if undertaken, or if such second distribution is not undertaken, any funds shall remain in the Net Settlement Fund after the Claims Administrator has made reasonable and diligent efforts to have Authorized Claimants who are entitled to participate in this Settlement cash their checks, any funds remaining in the Net Settlement Fund shall be donated to a non-profit charitable organization(s) agreed upon by the Parties.

THE BASIS FOR CALCULATING YOUR RECOGNIZED LOSS:

Each Authorized Claimant shall be allocated a *pro rata* share of the Net Settlement Fund based on his, her, or its Recognized Loss as compared to the total Recognized Losses of all Authorized Claimants. Recognized Losses will be calculated as follows:

For Amylyx common stock purchased or acquired during the Settlement Class Period, the Recognized Loss shall be calculated as follows:

- A. For shares retained at the end of trading on February 6, 2024, the Recognized Loss shall be the lesser of:
 - (i) \$4.80 per share; or
 - (ii) the difference between the purchase price per share and \$14.54 per share².
- B. For shares sold on or before November 8, 2023, the Recognized Loss per share shall be \$0.00.

²Pursuant to Section 21(D)(e)(1) of the Private Securities Litigation Reform Act of 1995, "in any private action arising under this title in which the plaintiff seeks to establish damages by reference to the market price of a security, the award of damages to the plaintiff shall not exceed the difference between the purchase or sale price paid or received, as appropriate, by the plaintiff for the subject security and the mean trading price of that security during the 90-day period beginning on the date on which the information correcting the misstatement or omission that is the basis for the action is disseminated." \$14.54 per share was the mean (average) daily closing trading price of the Company's shares during the 90-day period beginning on November 9, 2023, through and including February 6, 2024

C. For shares sold between November 9, 2023 and February 6, 2024, inclusive, the Recognized Loss shall be the lesser of:

- (i) \$4.80 per share: or
- (ii) the difference between the purchase price per share and the average closing price per share as of date of sale provided in Table A below.

Table A

Date	Closing Price	Average	Date	Closing Price	Average
		Closing Price			Closing Price
11/9/2023	\$12.26	\$12.26	12/22/2023	\$14.50	\$13.63
11/10/2023	\$12.48	\$12.37	12/26/2023	\$14.24	\$13.65
11/13/2023	\$12.94	\$12.56	12/27/2023	\$14.54	\$13.67
11/14/2023	\$12.52	\$12.55	12/28/2023	\$14.75	\$13.71
11/15/2023	\$13.08	\$12.66	12/29/2023	\$14.72	\$13.73
11/16/2023	\$12.13	\$12.57	1/2/2024	\$14.97	\$13.77
11/17/2023	\$12.07	\$12.50	1/3/2024	\$16.03	\$13.83
11/20/2023	\$12.91	\$12.55	1/4/2024	\$16.64	\$13.90
11/21/2023	\$12.64	\$12.56	1/5/2024	\$16.83	\$13.98
11/22/2023	\$12.71	\$12.57	1/8/2024	\$16.87	\$14.05
11/24/2023	\$13.17	\$12.63	1/9/2024	\$16.40	\$14.11
11/27/2023	\$12.93	\$12.65	1/10/2024	\$16.16	\$14.16
11/28/2023	\$12.91	\$12.67	1/11/2024	\$16.22	\$14.20
11/29/2023	\$13.58	\$12.74	1/12/2024	\$15.79	\$14.24
11/30/2023	\$14.16	\$12.83	1/16/2024	\$15.52	\$14.27
12/1/2023	\$14.22	\$12.92	1/17/2024	\$15.08	\$14.29
12/4/2023	\$14.46	\$13.01	1/18/2024	\$14.88	\$14.30
12/5/2023	\$14.88	\$13.11	1/19/2024	\$15.01	\$14.31
12/6/2023	\$15.09	\$13.22	1/22/2024	\$14.69	\$14.32
12/7/2023	\$14.22	\$13.27	1/23/2024	\$14.61	\$14.33
12/8/2023	\$14.00	\$13.30	1/24/2024	\$14.37	\$14.33
12/11/2023	\$14.25	\$13.35	1/25/2024	\$15.37	\$14.35
12/12/2023	\$14.71	\$13.41	1/26/2024	\$15.38	\$14.37
12/13/2023	\$14.72	\$13.46	1/29/2024	\$15.79	\$14.39
12/14/2023	\$14.74	\$13.51	1/30/2024	\$15.62	\$14.42
12/15/2023	\$14.23	\$13.54	1/31/2024	\$16.00	\$14.44
12/18/2023	\$14.19	\$13.56	2/1/2024	\$16.57	\$14.48
12/19/2023	\$13.98	\$13.58	2/2/2024	\$15.78	\$14.50
12/20/2023	\$13.81	\$13.59	2/5/2024	\$15.30	\$14.52
12/21/2023	\$13.95	\$13.60	2/6/2024	\$15.56	\$14.54

To the extent a Claimant had a trading gain or “broke even” from his, her, or its overall transactions in Amylyx common stock during the Settlement Class Period, the value of the Recognized Loss will be zero and the Claimant will not be entitled to a share of the Net Settlement Fund. To the

extent that a Claimant suffered a trading loss on his, her, or its overall transactions in Amylyx's common stock during the Settlement Class Period, but that trading loss was less than the Recognized Loss calculated above, then the Recognized Loss shall be limited to the amount of the Claimant's actual trading loss.

To determine whether a Claimant had a trading gain on his, her, or its overall transactions in Amylyx common stock during the Settlement Class Period, the Claims Administrator will determine the difference between the total amount paid for all shares of Amylyx common stock purchased during the Settlement Class Period, excluding any taxes, fees, or commissions paid on such purchases, minus the total amount received for all such shares of Amylyx common stock sold during the period from November 11, 2022 through the close of trading on February 6, 2024, excluding any taxes, fees, or commissions received for such sales. Any shares of Amylyx common stock purchased during the Settlement Class Period and still held as of the close of trading on February 6, 2024 will be incorporated in the overall calculation as the actual purchase price per share minus \$14.54 per share. Any shares of Amylyx common stock which were held as of the close of trading on November 10, 2022 and sold after the opening of trading on November 11, 2022 (i.e. during the Settlement Class Period or thereafter) will not be included in the overall calculation.

For purposes of calculating your Recognized Loss, the date of purchase, acquisition or sale is the "contract" or "trade" date and not the "settlement" or "payment" date. The receipt or grant by gift, inheritance or operation of law of Amylyx's common stock shall not be deemed a purchase or acquisition of Amylyx's common stock for the calculation of an Authorized Claimant's Recognized Loss. The covering purchase of a short sale is not an eligible purchase. Only publicly traded share are eligible purchases (Cusip number: _____).

For purposes of calculating your Recognized Loss, all purchases, acquisitions and sales shall be matched on a First In First Out ("FIFO") basis in chronological order. Therefore, on the Proof of Claim and Release Form enclosed with this Notice, you must provide all of your purchases, acquisitions and sales of Amylyx's common stock during the time period from November 11, 2022 through and including February 6, 2024.

Payment pursuant to the Plan of Allocation approved by the Court shall be conclusive against all Authorized Claimants. No person shall have any claim against Defendants, Defendants' Counsel, Lead Plaintiff, Lead Counsel, or the Claims Administrator or other agent designated by Lead Counsel based on the distributions made substantially in accordance with the Stipulation and the Settlement contained therein, the Plan of Allocation, or further orders of the Court. Each Claimant shall be deemed to have submitted to the jurisdiction of the Court with respect to the Claimant's Proof of Claim and Release Form. All persons involved in the review, verification, calculation, tabulation, or any other aspect of the processing of the claims submitted in connection with the Settlement, or otherwise involved in the administration or taxation of the Settlement Fund or the Net Settlement Fund, shall be released and discharged from any and all claims arising out of such involvement, and all Settlement Class Members, whether or not they are to receive payment from the Net Settlement Fund, will be barred from making any further claim against the Net Settlement Fund beyond the amount allocated to them as provided in any distribution orders entered by the Court.

SPECIAL NOTICE TO SECURITIES BROKERS AND OTHER NOMINEES

If you purchased or otherwise acquired Amylyx securities during the period from November 11, 2022 through November 8, 2023, inclusive, for the beneficial interest of a person or entity other than yourself, the Court has directed that, **within ten (10) calendar days of your receipt of notice**, you either (a) request the electronic Postcard Notice or the link to the electronic Notice and Proof of Claim form from the Claims Administrator, and **within ten (10) calendar days of receipt**, email the electronic Post-Card Notice or the link to the electronic Notice and Proof of Claim to all beneficial owners/purchasers for whom valid email addresses are available, (b) request from the Claims Administrator sufficient copies of the Post-Card Notice to forward to all such beneficial owners and, **within ten (10) calendar days of receipt**, forward them to all such beneficial owners, or (c) provide a list of the names, addresses, and email addresses (if any) of all such beneficial owners to the Claims Administrator, in which event the Claims Administrator will promptly mail the Postcard Notice or email the electronic Post-Card Notice to such identified beneficial owners. If you choose to follow procedure (a) or (b), the Court has directed that, upon such emailing or mailing, you must send a statement to the Claims Administrator confirming that the emailing or mailing was made as directed.

You may request reimbursement from the Settlement Fund for your reasonable out-of-pocket expenses actually incurred in connection with the foregoing, up to a maximum of \$0.02 per link to the Long Notice and Claim Form emailed; \$0.02 per Post-Card Notice, plus postage at the current pre-sort rate used by the Claims Administrator, for Post-Card Notices actually mailed; or \$0.02 per record consisting of name, address, and email address that is provided to the Claims Administrator. Expenses will be paid upon request and submission of appropriate supporting documentation and timely compliance with the above directives. All communications regarding the foregoing should be addressed to the Claims Administrator at the address listed on page 3 above.

DATED: _____, 2026

BY ORDER OF THE UNITED STATES
DISTRICT COURT FOR THE
DISTRICT OF MASSACHUSETTS

PROOF OF CLAIM AND RELEASE FORM
“PROOF OF CLAIM”

Deadline for Submission: _____, 2026

If you purchased or otherwise acquired Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) securities during the period from November 11, 2022, through November 8, 2023, inclusive (the “Settlement Class Period”), you may be a “Settlement Class Member” and you may be entitled to share in the Net Settlement Fund. (Excluded from the Settlement Class are Defendants; the officers and directors of Amylyx who served in their role between November 11, 2022 and November 8, 2023; members of their immediate families and their legal representatives, heirs, agents, affiliates, successors or assigns; Defendants’ liability insurance carriers, and any affiliates or subsidiaries thereof; any entity in which Defendants or their immediate families have or had a controlling interest between November 11, 2022 and November 8, 2023; and those persons who exclude themselves by submitting a request for exclusion from the Settlement Class that is accepted by the Court.)

If you are a Settlement Class Member, in order to be eligible for any Settlement benefits, you must complete and submit the electronic version of this Proof of Claim and Release Form (“Proof of Claim”) through the Settlement website at www.strategicclaims.net/Amylyx/ **no later than 11:59 p.m. ET on _____, 2026**, or you may alternatively complete and sign this Proof of Claim and Release Form and mail it by first class mail, postmarked **no later than _____, 2026**, to Strategic Claims Services, the Claims Administrator, at the following address:

Amylyx Pharmaceuticals, Inc. Securities Litigation
c/o Strategic Claims Services
600 N. Jackson St., Suite 205
P.O. Box 230
Media, PA 19063
Tel.: 866-274-4004
Fax: 610-565-7985
info@strategicclaims.net

Your failure to submit your Proof of Claim by _____, 2026 will subject your claim to rejection and preclude you from receiving any money in connection with the Settlement of this Action. Do not mail or deliver your Proof of Claim to the Court or to any of the parties or their counsel, as any such claim will be deemed not to have been submitted. Submit your claim only to the Claims Administrator. If you are a Settlement Class Member and do not submit a proper Proof of Claim and Release Form, you will not share in the Settlement, but you nevertheless will be bound by the Final Judgment of the Court unless you exclude yourself. Submission of a Proof of Claim and Release Form does not assure that you will share in the proceeds of the Settlement.

CLAIMANT'S STATEMENT

1. I (we) purchased or otherwise acquired securities of Amylyx Pharmaceuticals, Inc. ("Amylyx") between November 11, 2022, and November 8, 2023, inclusive ("the Settlement Class Period"). (Do not submit this Proof of Claim and Release Form if you did not purchase Amylyx securities during the Settlement Class Period.)

2. By submitting this Proof of Claim and Release Form, I (we) state that I (we) believe in good faith that I am (we are) a Settlement Class Member(s) as defined above and in the Notice of Pendency and Proposed Settlement of Class Action (the "Notice"), or am (are) acting for such person(s); that I am (we are) not a Defendant(s) in the Action or anyone excluded from the Settlement Class; that I (we) have read and understand the Notice; that I (we) believe that I am (we are) entitled to receive a share of the Net Settlement Fund, as defined in the Notice; that I (we) elect to participate in the proposed Settlement described in the Notice; and that I (we) have not filed a request for exclusion. (If you are acting in a representative capacity on behalf of a Settlement Class Member [e.g., as an executor, administrator, trustee, or other representative], you must submit evidence of your current authority to act on behalf of that Settlement Class Member. Such evidence would include, for example, letters testamentary, letters of administration, or a copy of the trust documents.)

3. I (we) consent to the jurisdiction of the Court with respect to all questions concerning the validity of this Proof of Claim and Release Form. I (we) understand and agree that my (our) claim may be subject to investigation and discovery under the Federal Rules of Civil Procedure, provided that such investigation and discovery shall be limited to my (our) status as a Settlement Class Member(s) and the validity and amount of my (our) claim. No discovery shall be allowed on the merits of the Action or Settlement in connection with processing of the Proof of Claim and Release Form.

4. I (we) have set forth where requested below all relevant information with respect to each purchase and/or acquisition of Amylyx securities, and each sale, if any, of such securities. I (we) agree to furnish additional information to the Claims Administrator to support this claim if requested to do so.

5. I (we) have provided photocopies or scanned stockbroker's confirmation slips, stockbroker's statements, or other documents evidencing each purchase, acquisition, and sale of Amylyx securities listed below in support of my (our) claim. (IF ANY SUCH DOCUMENTS ARE NOT IN YOUR POSSESSION, PLEASE OBTAIN A COPY OR EQUIVALENT DOCUMENTS FROM YOUR BROKER OR TAX ADVISOR BECAUSE THESE DOCUMENTS ARE NECESSARY TO PROVE AND PROCESS YOUR CLAIM. DO NOT SEND STOCK CERTIFICATES.)

6. I (we) understand that the information contained in this Proof of Claim and Release Form is subject to such verification as the Claims Administrator may request or as the Court may direct, and I (we) agree to cooperate in any such verification. (The information requested herein is designed to provide the minimum amount of information necessary to process most simple claims. The Claims Administrator may request additional information as required to efficiently and reliably calculate your Recognized Loss. In some cases, the Claims Administrator may condition acceptance of the claim based upon the production of additional information, including, where applicable, information concerning transactions in any derivatives securities such as options.)

7. NOTICE REGARDING ELECTRONIC FILES: Representatives with the authority to file on behalf of (a) accounts of multiple persons and/or (b) institutional accounts with large numbers of transactions (“Representative Filers”) must submit information regarding their clients’ transactions in the approved electronic spreadsheet format, which is available by request to the Claims Administrator at efile@strategicclaims.net or by visiting the website www.strategicclaims.net/Amylyx/. One spreadsheet may contain the information for multiple persons and institutional accounts, but all Representative Filers MUST also submit a manually signed Proof of Claim and Release Form, as well as proof of authority to file (see Item 2 of the Claimant’s Statement) along with the electronic spreadsheet. Any file not submitted in accordance with the required electronic filing format will be subject to rejection. No claims submitted in electronic spreadsheet format will be considered to have been properly submitted unless the Claims Administrator issues to the Claimant a written acknowledgment of receipt and acceptance of electronically submitted data. Do not assume that the file has been received or processed until the Claims Administrator sends a confirmation email. If you do not receive such an email within 10 days of submission, please contact the electronic filing department at efile@strategicclaims.net to inquire about the file and confirm it was received and acceptable.

8. NOTICE REGARDING ONLINE FILING: Claimants who are not Representative Filers may submit their claims online using the electronic version of the Proof of Claim and Release Form hosted at www.strategicclaims.net/Amylyx/. If you are not acting as a Representative Filer, you do not need to contact the Claims Administrator prior to filing; you will receive an automated e-mail confirming receipt once your Proof of Claim and Release Form has been submitted. If you are unsure if you should submit your claim as a Representative Filer, please contact the Claims Administrator at info@strategicclaims.net or (866) 274-4004. If you are not a Representative Filer, but your claim contains a large number of transactions, the Claims Administrator may request that you also submit an electronic spreadsheet showing your transactions to accompany your Proof of Claim and Release Form.

I. CLAIMANT INFORMATION

The Claims Administrator will use this information for all communications regarding this Claim Form. If this information changes, you **MUST** notify the Claims Administrator in writing at the address above. Complete names of all persons and entities must be provided.

Beneficial Owner Name		
Joint Beneficial Owner Name		
Address 1 (Street Name and Number)		
Address 2 (apartment, unit, or box number)		
City	State	ZIP
Foreign Province	Foreign Country	
Telephone Number (home)	Telephone Number (work)	
Email Address		
Account Number (if filing for multiple accounts, file a separate Claim Form for each account)		
Social Security Number (for individuals):	OR	Taxpayer Identification Number (for estates, trusts, corporations, etc.):

Claimant Account Type (check appropriate box):

- | | | |
|--|----|--|
| <input type="checkbox"/> Individual (includes joint owner accounts)
<input type="checkbox"/> Corporation
<input type="checkbox"/> IRA/401K | OR | <input type="checkbox"/> Pension Plan <input type="checkbox"/> Trust
<input type="checkbox"/> Estate
<input type="checkbox"/> Other _____ (please specify) |
|--|----|--|

II. SCHEDULE OF TRANSACTIONS IN AMYLYX PHARMACEUTICALS, INC. (“AMYLYX”) SECURITIES

Beginning Holdings:

A. State the total number of shares of Amylyx common stock held at the close of trading on November 10, 2022 (*must be documented*). If none, write “zero” or “0.”

Purchases/Acquisitions:

B. Separately list each and every purchase or acquisition of Amylyx common stock between November 11, 2022 and November 8, 2023, both dates inclusive, and provide the following information (*must be documented*):

Trade Date (List Chronologically) (Month/Day/Year)	Number of Shares Purchased/Acquired	Price per Share	Total Cost (Excluding Commissions, Taxes, and Fees)

Sales:

C. Separately list each and every sale or disposition of Amylyx common stock between November 11, 2022 and November 8, 2023, both dates inclusive, and provide the following information (*must be documented*):

Trade Date (List Chronologically) (Month/Day/Year)	Number of Shares Sold	Price per Share	Amount Received (Excluding Commissions, Taxes, and Fees)

Ending Holdings:

D. State the total number of shares of Amylyx common stock held at the close of trading on November 8, 2023 (*must be documented*).

If additional space is needed, attach separate, numbered sheets, giving all required information, substantially in the same format, and print your name and Social Security or Taxpayer Identification number at the top of each sheet.

III. SUBSTITUTE FORM W-9

Request for Taxpayer Identification Number

Enter taxpayer identification number below for the Beneficial Owner(s). For most individuals, this is your Social Security Number. The Internal Revenue Service (“I.R.S.”) requires such taxpayer identification number. If you fail to provide this information, your claim may be rejected.

Social Security Number (for individuals)	Or	Taxpayer Identification (for estates, trusts, corporations, etc.)

IV. RELEASE

1. I (We) hereby acknowledge full and complete satisfaction of, and do hereby fully, finally, and forever settle, release, relinquish and discharge with prejudice all of the Released Claims against each and all of the Released Parties (as these terms are defined in the Stipulation of Settlement, dated May 4, 2026, the “Stipulation”).

2. I (We) hereby acknowledge that I (we) will not be entitled to bring, or receive recovery in, any other action against any of the Released Parties based on or arising out of the Released Claims (as these terms are defined in the Stipulation).

3. This Release shall be of no force or effect unless and until the Court approves the Settlement and it becomes effective on the Effective Date.

4. I (We) hereby warrant and represent that I (we) am (are) a member of the Settlement Class and I (we) have not assigned or transferred or purported to assign or transfer, voluntarily or involuntarily, any matter released pursuant to this release or any other part or portion thereof.

V. CERTIFICATION

I (We) submit this Proof of Claim and Release Form under the terms of the Stipulation described in the Internet Notice. I (We) also submit to the jurisdiction of the United States District Court for the District of Massachusetts with respect to my (our) claim as a Settlement Class Member(s) and for purposes of enforcing the release and covenant not to sue set forth herein. I (We) further acknowledge that I am (we are) bound by and subject to the terms of any judgment that may be entered in this Action. I (We) have not submitted any other claim covering the same purchases or sales of Amylyx securities during the Settlement Class Period and know of no other person having done so on my (our) behalf.

I (We) certify that I am (we are) NOT subject to backup withholding under the provisions of Section 3406(a)(1)(c) of the Internal Revenue Code because: (a) I am (We are) exempt from backup withholding; or (b) I (We) have not been notified by the I.R.S. that I am (we are) subject to backup withholding as a result of a failure to report all interest or dividends; or (c) the I.R.S. has notified me (us) that I am (we are) no longer subject to backup withholding.

NOTE: If you have been notified by the I.R.S. that you are subject to backup withholding, please strike out the language that you are not subject to backup withholding in the certification above.

UNDER THE PENALTIES OF PERJURY UNDER THE LAWS OF THE UNITED STATES, I (WE) CERTIFY THAT ALL OF THE INFORMATION I (WE) PROVIDED ON THIS PROOF OF CLAIM AND RELEASE FORM IS TRUE, CORRECT, AND COMPLETE, AND I (WE) AGREE TO BE BOUND BY ALL ORDERS ENTERED IN THE ACTION.

Signature of Claimant (If this claim is being made on behalf of Joint Claimants, then each must sign):

(Signature)

(Signature)

(Capacity of person(s) signing, e.g. beneficial purchaser(s), executor, administrator, trustee, etc.)

Check here if proof of authority to file is enclosed.
(See III, above)

You should be aware that it will take a significant amount of time to process fully all of the Proof of Claim and Release Forms and to administer the Settlement. This work will be completed as promptly as time permits, given the need to investigate and tabulate each Proof of Claim and Release Form. Please notify the Claims Administrator of any change of address.

REMINDER CHECKLIST

- Please be sure to sign this Proof of Claim and Release Form on page 7. If this Proof of Claim and Release Form is submitted on behalf of joint claimants, then both claimants must sign.
- Please remember to attach or scan supporting documents. Do NOT send any stock certificates. Keep copies of everything you submit.
- Do NOT use highlighter on the Proof of Claim and Release Form or any supporting documents.
- If you move or change your address, telephone number, or email address, please submit the new information to the Claims Administrator, as well as any other information that will assist us in contacting you. NOTE: Failure to submit updated information to the Claims Administrator may result in the Claims Administrator's inability to contact you regarding issues with your claim or to deliver payment to you.

**UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS**

OLIVER SHIH, Individually and on Behalf of
All Others Similarly Situated,

Plaintiff, v.

AMYLYX PHARMACEUTICALS, INC.,
JOSHUA B. COHEN, JUSTIN B. KLEE,
JAMES M. FRATES, and MARGARET
OLINGER,

Defendants.

Case No. 1:24-cv-12068-NMG

**SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT
OF CLASS ACTION**

To: All those who purchased or otherwise acquired Amylyx Pharmaceuticals, Inc. (“Amylyx”) securities between November 11, 2022, and November 8, 2023, inclusive (the “Class Period”), and who were allegedly damaged thereby (the “Settlement Class”).

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the District of Massachusetts, that Plaintiff Oliver Shih, on behalf of himself and all members of the proposed Settlement Class, and Amylyx, Joshua B. Cohen, Justin B. Klee, James M. Frates, and Margaret Olinger (collectively, “Defendants”) have reached a proposed settlement of the claims against the Defendants in the above-captioned class action (the “Action”) in the amount of \$6,500,000 (the “Settlement”).

A hearing will be held before the Honorable Nathaniel M. Gorton either in person or remotely, at the Court’s discretion, on _____, 2026, at _____.m. at the United States District Court for the District of Massachusetts, Courtroom No. 4, 3rd Floor, 1 Courthouse Way, Boston, Massachusetts, 02210 (the “Settlement Hearing”) to determine whether the Court should: (i) approve the proposed Settlement as fair, reasonable, and adequate; (ii) dismiss the Action with prejudice as provided in the Stipulation of Settlement, dated May 4, 2026; (iii) approve the

proposed Plan of Allocation for distribution of the proceeds of the Settlement (the “Net Settlement Fund”) to Settlement Class Members; and (iv) approve Lead Counsel’s application for attorneys’ fees, litigation expenses, and award to Plaintiff. The Court may change the date of the Settlement Hearing, or hold it remotely, without providing another written notice. Information about the hearing will be posted at www.strategicclaims.net/Amylyx/. You do NOT need to attend the Settlement Hearing to receive a distribution from the Net Settlement Fund.

IF YOU ARE A MEMBER OF THE SETTLEMENT CLASS, YOUR RIGHTS WILL BE AFFECTED BY THE PROPOSED SETTLEMENT AND YOU MAY BE ENTITLED TO A MONETARY PAYMENT. If you have not yet received a full Notice of Pendency and Proposed Settlement of Class Action (“Notice”) and Proof of Claim and Release Form (“Proof of Claim”), you may obtain copies of these documents by visiting www.strategicclaims.net/Amylyx/ or by contacting the Claims Administrator at:

Amylyx Pharmaceuticals, Inc. Securities Litigation
c/o Strategic Claims Services
600 N. Jackson Street, Suite 205
P.O. Box 230
Media, PA 19063
Toll-Free: (866) 274-4004
Fax: (610) 565-7985
info@strategicclaims.net

Inquiries, other than requests for information about the status of a claim or for copies of the Notice and Proof of Claim, may also be made to Lead Counsel:

POMERANTZ LLP
Jeremy A. Lieberman, Esq.
Samantha Daniels, Esq.
600 Third Avenue, 20th Floor
New York, NY 10016
www.pomlaw.com
(212) 661-1100

If you are a Settlement Class Member, to be eligible to share in the distribution of the Net Settlement Fund, you must submit a Proof of Claim *postmarked or submitted online no later than* _____, **2026**. If you are a Settlement Class Member and do not timely submit a valid Proof of Claim, you will not be eligible to share in the distribution of the Net Settlement Fund, but you will nevertheless be bound by all judgments or orders entered by the Court relating to the Settlement, whether favorable or unfavorable.

If you are a Settlement Class Member and wish to exclude yourself from the Settlement Class, you must submit a written request for exclusion in accordance with the instructions set forth in the Notice so that it is *received no later than* _____, **2026**. If you properly exclude yourself from the Settlement Class, you will not be bound by any judgments or orders entered by the Court relating to the Settlement, whether favorable or unfavorable, and you will not be eligible to share in the distribution of the Net Settlement Fund.

Any objections to the proposed Settlement; Lead Counsel's application for awards of attorneys' fees, expenses, and award to Lead Plaintiff; and/or the proposed Plan of Allocation must be submitted to counsel for the Parties in accordance with the instructions in the Notice, such that they are *received no later than* _____, **2026**.

**PLEASE DO NOT CONTACT THE COURT, DEFENDANTS, OR
DEFENDANTS' COUNSEL REGARDING THIS NOTICE.**

DATED: _____, 2026

BY ORDER OF THE COURT
UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS

**Court-Ordered Legal Notice
Forwarding Service Requested**

*Important Notice about a Securities
Class Action Settlement*

*You may be entitled to a payment.
This Notice may affect your legal
rights.*

Please read it carefully.

ACTIVE/206716715.1

Amylyx Pharmaceuticals, Inc.
Securities Litigation
c/o Strategic Claims Services
600 N. Jackson St., Ste. 205
Media, PA 19063

PRESORTED
FIRST-CLASS
MAIL U.S.
POSTAGE PAID

Case No. 1:24-cv-12068-NMG
(D.Mass)

Case Pending in the United States District Court for the
District of Massachusetts

[NAME 1]
[NAME 2]
[NAME 3]
[ADDRESS 1]
[ADDRESS 2]

ACTIVE/206716715.1

SHIH v. AMYLYX PHARMACEUTICALS, INC., et al., Case No. 1:24-cv-12068-NMG (D. Mass)

THIS CARD PROVIDES ONLY LIMITED INFORMATION ABOUT THE SETTLEMENT.

PLEASE VISIT WWW.STRATEGICCLAIMS.NET/AMYLYX/ OR CALL 1-866-274-4004 FOR MORE INFORMATION.

The United States District Court for the District of Massachusetts (the “Court”) has preliminarily approved a proposed Settlement of all claims against Amylyx Pharmaceuticals, Inc. (“Amylyx” or “Company”), Joshua B. Cohen, Justin B. Klee, James M. Frates, and Margaret Olinger (collectively, the “Defendants”). The proposed Settlement would resolve a class action lawsuit alleging that, in violation of the federal securities laws, Defendants made false and misleading statements regarding the success of the commercial launch of the Company’s product Relyvrio.

You received this notice because you may have purchased or acquired Amylyx securities between November 11, 2022, and November 8, 2023, inclusive, and you may be a Settlement Class Member. The Settlement provides that, in exchange for the dismissal and release of claims against Defendants, a fund consisting of \$6,500,000, less attorneys’ fees and expenses, will be divided among Settlement Class Members who timely submit a valid Proof of Claim and Release Form (“Proof of Claim”). For a full description of the Settlement and your rights and to make a claim, please view the Stipulation of Settlement at www.strategicclaims.net/Amylyx/. To obtain a copy of the Notice of Pendency and Proposed Settlement of Class Action (“Notice”) and Proof of Claim, visit the website: www.strategicclaims.net/Amylyx/ or request copies from the Claims Administrator through any of the following ways: (1) mail: Amylyx Pharmaceuticals, Inc. Securities Litigation, c/o Strategic Claims Services, 600 N. Jackson St., Ste. 205, P.O. Box 230, Media, PA 19063; (2) call toll-free: 1 (866)-274-4004; (3) fax: (610) 565-7985; or (4) email: info@strategicclaims.net.

To qualify for payment, you must submit a Proof of Claim, which can be found on the website www.strategicclaims.net/Amylyx/. PROOFS OF CLAIM ARE DUE BY _____, 2026 TO AMYLYX PHARMACEUTICALS, INC. SECURITIES LITIGATION, C/O STRATEGIC CLAIMS SERVICES, 600 N. JACKSON ST., STE. 205, P.O. BOX 230, MEDIA, PA 19063. If you do not want to be legally bound by the Settlement, you must exclude yourself by _____, 2026. If you exclude yourself, you cannot get money from this Settlement. If you stay in the Settlement, you may object to it by _____, 2026. The Notice explains how to exclude yourself or to object.

The Court will hold a hearing in this case on _____, 2026 at _____.m. at the United States District Court for the District of Massachusetts, Courtroom No. 4, 3rd Floor, 1 Courthouse Way, Boston, Massachusetts, 02210, to consider whether to approve the Settlement, the Plan of Allocation, and a request by Lead Counsel for up to 33 ⅓% plus interest of the Settlement

ACTIVE/206716715.1

Fund in attorneys' fees; up to \$ [REDACTED] in expenses; and an award to Plaintiff of no more than \$2,500 for litigating the case and negotiating the Settlement. You may, but do not have to, attend the hearing and ask to be heard by the Court. For more information, call toll-free 1 (866) 274-4004, or visit the website www.strategicclaims.net/Amylyx/.

EXHIBIT B

**UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS**

OLIVER SHIH, Individually and on behalf of
all others similarly situated,

Plaintiff,

v.

AMYLYX PHARMACEUTICALS, INC.,
JOSHUA B. COHEN, JUSTIN B. KLEE,
JAMES M. FRATES, and MARGARET
OLINGER,

Defendants.

Case No: 1:24-cv-12068-NMG

**[PROPOSED] ORDER AND FINAL
JUDGMENT**

This matter came before the Court for a hearing on the ____ day of _____, 20____, on the application of the Settling Parties for approval of the Settlement set forth in the Stipulation of Settlement dated May 4, 2026 (the “Settlement Stipulation”).

It appearing in the record that (a) the Post-Card Notice and the Notice substantially in the forms approved by the Court in the Court’s Preliminary Approval Order dated _____, 20____ (“Preliminary Approval Order”) were provided or made available to all reasonably identifiable Settlement Class Members and posted to the website of the Claims Administrator, both in accordance with the Preliminary Approval Order and the specifications of the Court; and (b) the Summary Notice substantially in the form approved by the Court in the Preliminary Approval Order was published in accordance with the Preliminary Approval Order and the specifications of the Court;

The Court having considered all papers filed and proceedings in the Action and otherwise being fully informed of the matters herein and good cause appearing therefore,

NOW, THEREFORE, IT IS HEREBY ORDERED, ADJUDGED AND DECREED THAT:

1. All capitalized terms used herein have the same meanings as set forth and defined in the Settlement Stipulation.

2. The Court has jurisdiction over the subject matter of the Action and over the Settling Parties.

3. The Court finds, for purposes of this Settlement only, that the prerequisites for a class action under Rule 23(a) and (b)(3) of the Federal Rules of Civil Procedure have been satisfied in that: (a) the number of Settlement Class Members is so numerous that joinder of all members thereof is impracticable; (b) there are questions of law and fact common to the Settlement Class; (c) Plaintiff's claims are typical of the claims of the Settlement Class he seeks to represent; (d) Plaintiff fairly and adequately represents the interests of the Settlement Class; (e) questions of law and fact common to the members of the Settlement Class predominate over any questions affecting only individual members of the Settlement Class; and (f) a class action is superior to other available methods for the fair and efficient adjudication of this Action.

4. The Court hereby finally certifies this action as a class action for purposes of the Settlement, pursuant to Rule 23(a) and (b)(3) of the Federal Rules of Civil Procedure, on behalf of the "Settlement Class," defined as all those who purchased or otherwise acquired Amylyx securities between November 11, 2022, and November 8, 2023, inclusive, and who were damaged thereby. Excluded from the Settlement Class are Defendants; the officers and directors of Amylyx

during the Settlement Class Period; members of their immediate families and their legal representatives, heirs, agents, affiliates, successors, or assigns; Defendants' liability insurance carriers, and any affiliates or subsidiaries thereof; any entity in which Defendants or their immediate families have or had a controlling interest during the Settlement Class Period; and those persons who exclude themselves by submitting a request for exclusion from the Settlement Class that is accepted by the Court.

5. Pursuant to Rule 23 of the Federal Rules of Civil Procedure, for purposes of the Settlement only, Plaintiff is certified as the class representative on behalf of the Settlement Class ("Class Representative") and Lead Counsel, Pomerantz LLP, previously selected by Plaintiff and appointed by the Southern District of New York, is hereby appointed as Class Counsel for the Settlement Class ("Class Counsel").

6. In accordance with the Court's Preliminary Approval Order, the Court hereby finds that the forms and methods of notifying the Settlement Class of the Settlement and its terms and conditions: (a) met the requirements of due process, Rule 23 of the Federal Rules of Civil Procedure, and Section 21D(a)(7) of the Exchange Act, 15 U.S.C. § 78u-4(a)(7), as amended by the Private Securities Litigation Reform Act of 1995 and all other applicable laws; (b) constituted the best notice practicable under the circumstances; (c) were reasonably calculated under the circumstances to describe the terms and effect of the Settlement and to apprise Settlement Class Members of their right to object to the proposed Settlement, to appear at the Final Approval Hearing, to exclude themselves from the Settlement Class, as well as the binding effect of the orders and judgments in this Action; and (d) constituted due and sufficient notice to all those entitled thereto. No Settlement Class Member shall be relieved from the terms and conditions of the Settlement, including the releases provided pursuant thereto, based upon the contention or

proof that such Settlement Class Member failed to receive actual or adequate notice. A full opportunity has been offered to the Settlement Class Members to object to the proposed Settlement and to participate in the hearing thereon. The Court further finds that the notice provisions of the Class Action Fairness Act, 28 U.S.C. § 1715, were fully discharged.

7. The Settlement is approved as fair, reasonable and adequate under Rule 23 of the Federal Rules of Civil Procedure, and in the best interests of the Settlement Class. This Court further finds that the Settlement set forth in the Settlement Stipulation is the result of good faith, arm's-length negotiations between experienced counsel representing the interests of the Class Representative, Settlement Class Members, and Defendants. The Parties are directed to consummate the Settlement in accordance with the terms and provisions of the Settlement Stipulation.

8. The Action and all of the Released Claims are dismissed with prejudice as against each and all of the Defendants. The Parties are to bear their own costs, except as otherwise provided in the Settlement Stipulation.

9. In accordance with Paragraph 1.34 of the Settlement Stipulation, for purposes of this Final Judgment, the term "Releasing Parties" shall mean: Plaintiff, each and every Settlement Class Member and each of their respective parent entities, associates, affiliates, subsidiaries, predecessors, successors, assigns, attorneys, immediate family members, heirs, representatives, administrators, executors, devisees, legatees, and estates.

10. In accordance with Paragraph 1.32 of the Settlement Stipulation, for purposes of this Final Judgment, the term "Released Parties" shall mean (a) any and all of the Defendants and any person, partnership, firm, corporation, limited liability company, trust, or other entity or organization in which any Defendant has a controlling interest or which is or was related to or affiliated with any of the Defendants; (b) with respect to each of the Persons in subsection (a), their

respective past, present and future directors, officers, employees, managers, controlling shareholders, servants, insurers, co-insurers, reinsurers, attorneys, agents, partners, limited partners, principals, members, trustees, advisors, investment advisors, auditors, accountants, trustees, underwriters, investment bankers, consultants, subsidiaries, parents, any other entity in which any such parent has a controlling interest or which is or was related to or affiliated with any such parent, successors, predecessors, heirs, immediate family members, and anyone acting or purporting to act for or on behalf of any of them or their successors; and (c) the legal representatives, predecessors, heirs, successors and assigns of any of the foregoing.

11. In accordance with Paragraph 1.31 of the Settlement Stipulation, for purposes of this Final Judgment, the term “Released Claims” shall mean, to the fullest extent permitted by law or equity, claims, demands, losses, costs, interest, penalties, fees, attorneys’ fees, expenses, rights, rights of recovery, causes of action, duties, obligations, judgments, actions, debts, sums of money, suits, contracts, agreements, promises, damages, and liabilities of every nature and description, including Unknown Claims, whether known or unknown, direct or indirect, representative, class, individual, asserted or unasserted, matured or unmatured, accrued or unaccrued, foreseen or unforeseen, disclosed or undisclosed, contingent or fixed or vested, at law or equity, whether arising under federal, state, local, foreign, statutory, common, administrative, or any other law, statute, rule, or regulation that the Releasing Parties: (a) asserted in the Action; (b) could have asserted or could in the future assert in this Action or any other action or in any forum, that arise from or out of, relate to, or are in connection with the claims, allegations, transactions, alleged or actual prohibited transactions or breaches of duty (including fiduciary duty), facts, events, acts, disclosures, matters or occurrences, errors, statements, representations, actions, failures to act or omissions involved, alleged, described, set forth, or referred to in the complaint and amended

complaint filed in the Action, or that arise from or out of, relate to, directly or indirectly, or are in connection with the holding, purchase, acquisition, or sale of Amylyx Pharmaceuticals, Inc. securities during the Settlement Class Period (including, without limitation, claims for fraud and negligent misrepresentation); or (c) that arise out of, relate to, or are based on the settlement or resolution of the Action; provided, however, that Released Claims do not include claims to enforce the Stipulation. Released Claims do not include claims asserted in the derivative actions currently pending in the District of Massachusetts and Delaware Chancery Court.

12. In accordance with Paragraph 1.33 of the Settlement Stipulation, for purposes of this Final Judgment, the term “Released Parties’ Claims” shall mean: all claims, demands, rights, remedies, liabilities, and causes of action of every nature and description whatsoever, whether based on federal, state, local, statutory, or common law, or any other law, rule, or regulation, including both known and Unknown Claims, that arise out of or relate in any way to the institution, prosecution, or Settlement of this Action, including but not limited to all claims for malicious prosecution or sanctions. “Released Parties’ Claims” do not include claims to enforce any of the terms of this Stipulation or the Judgment or Alternate Judgment, if applicable.

13. In accordance with Paragraph 1.44 of the Settlement Stipulation, for purposes of this Final Judgment, the term “Unknown Claims” shall mean: (i) any Released Claims of which Plaintiff, any Settlement Class Member, or any Releasing Party does not know or suspect to exist in his, her, or its favor at the time of the Effective Date, and (ii) any Released Parties’ Claims which any Defendant or Released Party does not know or suspect to exist in his, her, or its favor at the time of the Effective date, which, if known by him, her, or it, might have affected his, her, or its decisions with respect to this Settlement, or any Settlement Class Member’s or Releasing Party’s decision not to opt-out or object to this Settlement. With respect to any and all Released

Claims or Releasing Parties' Claims, the Parties stipulate and agree that, upon the Effective Date, Plaintiff and Defendants shall expressly waive, and each of the Settlement Class Members, Releasing Parties, and Released Parties shall be deemed to have waived, and by operation of the Judgment or Alternate Judgment, if applicable, shall have waived, the provisions, rights and benefits of California Civil Code § 1542, which provides:

A general release does not extend to claims which the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release, and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

Plaintiff and Defendants acknowledge, and each of the Settlement Class Members, the Releasing Parties, and/or the Released Parties shall be deemed by operation of law to have acknowledged, that they may hereafter discover facts in addition to or different from those which he, she, or it now knows or believes to be true with respect to the subject matter of the Released Claims or Released Parties' Claims, but the Defendants and Plaintiff shall expressly, fully, finally, and forever settle and release, and each Settlement Class Member, Releasing Party, or Released Party, upon the Effective Date, shall be deemed to have, and by operation of the Judgment or Alternate Judgment, if applicable, shall have, fully, finally, and forever settled and released, any and all Released Claims or Released Parties' Claims, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of fiduciary duty, law, or rule, without regard to the subsequent discovery or existence of such different or additional facts. Plaintiff and Defendants acknowledge, and the Settlement Class Members and Released Parties shall be deemed by operation of the Judgment or Alternate

Judgment, if applicable, to have acknowledged, that the foregoing waiver was separately bargained for and a key element of the Settlement.

14. The Releasing Parties, on behalf of themselves, their past, present, and future heirs, executors, administrators, trustees, predecessors, successors and assigns, and any other Person claiming (now or in the future) to be acting on behalf of any of them, regardless of whether any such Releasing Party ever seeks or obtains by any means, including without limitation by submitting a Proof of Claim, any disbursement from the Settlement Fund, (a) shall have and be deemed to have, and by operation of the Judgment, or Alternate Judgment, shall have, irrevocably and unconditionally, fully, finally, and forever released, waived, relinquished, discharged, and dismissed, with prejudice, all Released Claims against the Released Parties; (b) shall have and be deemed to have covenanted not to sue, directly or indirectly any Released Party with respect to any and all of the Released Claims; and (c) shall be forever and permanently barred and enjoined from directly or indirectly filing, commencing, instituting, continuing, asserting, intervening in, or prosecuting, or assisting any Person in instituting, continuing, asserting or prosecuting in any forum, any Released Claim, in any capacity, against any of the Released Parties. Nothing contained herein shall, however, bar the Releasing Parties from bringing any action or claim to enforce the terms of the Settlement Stipulation or this Final Judgment.

15. Defendants, on behalf of themselves, their heirs, executors, predecessors, successors and assigns, shall be deemed to have, and by operation of this Final Judgment shall have, fully, finally, and forever released, relinquished, and discharged the Class Representative, Settlement Class Members, and Class Counsel from all Released Parties' Claims, and shall be permanently enjoined from prosecuting the Released Parties' Claims against Class Representative, Settlement Class Members, and Class Counsel. Nothing contained herein shall, however, bar the Defendants

or any Released Party from bringing any action or claim to enforce the terms of the Settlement Stipulation or this Final Judgment.

16. All Persons whose names appear on Exhibit 1 hereto are hereby excluded from the Settlement Class, are not bound by this Final Judgment, and may not make any claim with respect to or receive any benefit from the Settlement. Such excluded Persons may not pursue any Released Claims on behalf of those who are bound by this Final Judgment.

17. To the fullest extent permitted by law, all Persons shall be permanently enjoined, barred and restrained from bringing, commencing, prosecuting or asserting any claims, actions, or causes of action for contribution, indemnity or otherwise against any of the Released Parties seeking as damages or otherwise the recovery of all or any part of any liability, judgment or settlement which they pay or are obligated to pay or agree to pay to the Settlement Class or any Settlement Class Member arising out of, relating to or concerning such Person's participation in any acts, facts, statements or omissions that were or could have been alleged in the Action, whether arising under state, federal or foreign law as claims, cross-claims, counterclaims, third-party claims or otherwise, in the Court or any other federal, state, or foreign court, or in any arbitration proceeding, administrative agency proceeding, tribunal, or any other proceeding or forum. Further, nothing in the Settlement Stipulation or this Final Judgment shall apply to bar or otherwise affect any claim for insurance coverage by any Defendant.

18. The Court finds that all Settling Parties and their respective counsel have complied with all requirements of Rule 11 of the Federal Rules of Civil Procedure and the Private Securities Litigation Reform Act of 1995 as to all proceedings herein.

19. This Final Judgment, the Settlement Stipulation, any of their respective terms and provisions, and any negotiations, proceedings, or agreements relating to the Settlement Stipulation,

as well as all matters arising in connection with such negotiations, proceedings, or agreements, and all acts performed or documents executed pursuant to or in furtherance of the Settlement Stipulation:

(a) shall not be offered or received against any of the Defendants as evidence of a presumption, concession, or admission of any kind;

(b) shall not be offered or received against any of the Defendants as evidence of an admission by any of those Defendants with respect to the truth of any fact alleged in the Amended Complaint or the validity of any Released Claim, or the deficiency of any defense that has been or could have been asserted, or of any liability, negligence, fault, or wrongdoing of the Defendants;

(c) shall not be offered or received against the Defendants as evidence of any fault, misrepresentation, omission or other actionable conduct with respect to any statement or written document approved or made by any of the Defendants;

(d) shall not be offered or received against the Defendants as evidence of any liability, negligence, fault or wrongdoing, or in any way referred to for any other reason as against any of the Defendants, in any other civil, criminal, or administrative action or proceeding, other than such proceedings as may be necessary to effectuate the provisions of the Settlement Stipulation; provided, however, that if the Settlement Stipulation is approved by the Court, the Released Persons may refer to it to effectuate the release of Released Claims and other liability protections granted them hereunder;

(e) shall not be construed against any of the Defendants as an admission or concession that the consideration to be given hereunder represents the amount that could be or would have been recovered after trial;

(f) shall not be construed as or received in evidence as an admission, concession, or presumption against Class Representative or any of the Settlement Class Members that any of their claims are without merit, or that any defenses asserted by the Defendants have any merit, or that damages recoverable in the Action would not have exceeded the Settlement Amount; and

(g) shall not, in the event of a Termination, be used by any Party for any purpose in any trial in this Action.

20. The Released Parties may file or introduce the Settlement Stipulation and/or this Final Judgment in any action or proceeding that may be brought against them in order to support a defense or counterclaim based on principles of res judicata, collateral estoppel, full faith and credit, release, good faith settlement, judgment bar or reduction or any other theory of claim preclusion or issue preclusion or similar defense or counterclaim, or to otherwise enforce the terms of the Stipulation or this Final Judgment.

21. Except as otherwise provided herein or in the Settlement Stipulation, all funds held by the Escrow Agent shall be deemed to be in custodia legis and shall remain subject to the jurisdiction of the Court until such time as the funds are distributed or returned pursuant to the Settlement Stipulation and/or further order of the Court.

22. Without affecting the finality of this Final Judgment in any way, this Court hereby retains exclusive jurisdiction over (a) implementation of the Settlement and any award or distribution from the Settlement Fund, including to the Claims Administrator; (b) disposition of the Net Settlement Fund; (c) hearing and determining applications for attorneys' fees and expenses and any Award to Plaintiff; and (d) all Settling Parties for the purpose of construing, enforcing and administering the Settlement.

23. Without further order of the Court, the Defendants and Class Representative may agree in writing to such amendments, modifications, and expansions of the Settlement Stipulation, and reasonable extensions of time to carry out any of the provisions of the Settlement Stipulation, provided that such amendments, modifications, expansions, and extensions do not materially limit the rights of Settlement Class Members or the Released Parties under the Settlement Stipulation.

24. The finality of this Final Judgment approving the Settlement shall not be affected, in any manner, by rulings that the Court has made, or may in the future make, on the Plan of Allocation, Class Counsel's application for an award of attorneys' fees and expenses, or any award to Plaintiff, or any appeal or modification of any orders relating to the foregoing. Such matters shall be considered separate from final approval of the Settlement.

25. The Court hereby finds that the proposed Plan of Allocation is a fair and reasonable method to allocate the Net Settlement Fund among Settlement Class Members, and Class Counsel and the Claims Administrator are directed to administer the Plan of Allocation in accordance with its terms and the terms of the Settlement Stipulation.

26. In the event the Settlement does not become effective in accordance with the terms of the Settlement Stipulation, then the Settlement Stipulation and this Final Judgment shall be null and void to the extent provided by and in accordance with the Settlement Stipulation, and shall be vacated, and in such event, the provisions of Paragraph 10.6 of the Settlement Stipulation shall apply.

27. There is no just reason for delay in the entry of this Order and Final Judgment and immediate entry by the Clerk of the Court is expressly directed pursuant to Rule 54(b) of the Federal Rules of Civil Procedure.

Dated: _____, 2026

HON. NATHANIEL M. GORTON
SENIOR UNITED STATES DISTRICT JUDGE
United States District Court
District of Massachusetts